0001144204-16-102533.txt : 20160516 0001144204-16-102533.hdr.sgml : 20160516 20160516160145 ACCESSION NUMBER: 0001144204-16-102533 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160516 DATE AS OF CHANGE: 20160516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 161653548 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 10-Q 1 v439570_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

———————

FORM 10-Q

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the transition period from to

Commission File Number 0-18170

———————

BioLife Solutions, Inc.

(Exact name of registrant as specified in its charter)

———————

DELAWARE

94-3076866

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL, WASHINGTON, 98021

(Address of registrant’s principal executive offices, Zip Code)

(425) 402-1400

(Telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (S232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post said files). Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer ¨ Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No þ

As of May 11, 2016, 12,693,017 shares of the registrant’s common stock were outstanding.

BIOLIFE SOLUTIONS, INC.

FORM 10-Q

FOR THE QUARTER ENDED MARCH 31, 2016

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION		3

Item 1.	Consolidated Financial Statements	3

	Consolidated Balance Sheets as of March 31, 2016 (unaudited) and December 31, 2015	3

	Consolidated Statements of Operations (unaudited) for the three month periods ended March 31, 2016 and 2015	4

	Consolidated Statements of Comprehensive (Loss) (unaudited) for the three month periods ended March 31, 2016 and 2015	5

	Consolidated Statements of Cash Flows (unaudited) for the three month periods ended March 31, 2016 and 2015	6

	Notes to Consolidated Financial Statements (unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	17

Item 4.	Controls and Procedures	17

PART II.	OTHER INFORMATION	17

Item 6.	Exhibits	17

	Signatures	18

	Index to Exhibits	19

PART I. FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

BioLife Solutions, Inc.

Consolidated Balance Sheets

(Unaudited)

	March 31,			December 31,
	2016			2015
Assets
Current assets
Cash and cash equivalents	$	1,662,431		$	2,173,258
Short term investments		––			1,651,341
Accounts receivable, trade, net of allowance for doubtful accounts of $0 at March 31, 2016 and December 31, 2015		1,190,260			929,289
Inventories		2,018,255			1,834,635
Prepaid expenses and other current assets		435,592			384,414
Total current assets		5,306,538			6,972,937

Property and equipment
Leasehold improvements		1,284,491			1,284,491
Furniture and computer equipment		584,603			557,666
Manufacturing and other equipment		1,025,521			1,025,521
Subtotal		2,894,615			2,867,678
Less: Accumulated depreciation		(1,513,071	)		(1,421,279	)
Net property and equipment		1,381,544			1,446,399
Internal use software		1,836,220			1,698,735
Intangible asset		2,215,385			2,215,385
Long term deposits		36,166			36,166
Total assets	$	10,775,853		$	12,369,622

Liabilities and Shareholders’ Equity
Current liabilities
Accounts payable	$	772,870		$	1,029,373
Accrued expenses and other current liabilities		113,340			146,438
Accrued compensation		463,558			419,766
Deferred rent		130,216			130,216
Total current liabilities		1,479,984			1,725,793
Long term liabilities
Deferred rent, long term		766,044			784,458
Total liabilities		2,246,028			2,510,251

Commitments and contingencies (Note 9)

Shareholders’ equity
Common stock, $0.001 par value; 150,000,000 shares authorized, 12,508,376 and 12,448,391 shares issued and outstanding at March 31, 2016 and December 31, 2015		12,508			12,447
Additional paid-in capital		72,983,853			72,823,398
Accumulated other comprehensive loss		––			(451	)
Accumulated deficit		(65,553,751	)		(64,326,923	)
Total BioLife Solutions, Inc. shareholders’ equity		7,442,610			8,508,471
Total non-controlling interest equity		1,087,215			1,350,900
Total shareholders’ equity		8,529,825			9,859,371
Total liabilities and shareholders’ equity	$	10,775,853		$	12,369,622

The accompanying Notes to Consolidated Financial Statements are an integral part of these consolidated financial statements

BIoLife Solutions, Inc.

Consolidated Statements of Operations

(unaudited)

	Three Month Period Ended March 31,
	2016			2015
Product revenue	$	1,852,017		$	1,500,722
Cost of product sales		771,005			618,099
Gross profit		1,081,012			882,623
Operating expenses
Research and development		504,239			322,165
Sales and marketing		733,913			500,255
General and administrative		1,335,292			1,220,705
Total operating expenses		2,573,444			2,043,125

Operating loss		(1,492,432	)		(1,160,502	)

Other income
Interest income		1,919			8,237

Net Loss		(1,490,513	)		(1,152,265	)
Net loss attributable to non-controlling interest		263,685			120,783
Net Loss attributable to BioLife Solutions, Inc.	$	(1,226,828	)	$	(1,031,482	)

Basic and diluted net loss per common share attributable to BioLife Solutions, Inc.	$	(0.10	)	$	(0.09	)

Basic and diluted weighted average common shares used to calculate net loss per common share		12,457,858			12,100,588

The accompanying Notes to Consolidated Financial Statements are an integral part of these consolidated financial statements

BIoLife Solutions, Inc.

Consolidated Statements of Comprehensive Loss

(unaudited)

	Three Month Period Ended March 31,
	2016			2015
Net loss	$	(1,490,513	)	$	(1,152,265	)

Other comprehensive income
Unrealized gain on available-for-sale investments		451			5,499
Total other comprehensive income		451			5,499

Comprehensive loss		(1,490,062	)		(1,146,766	)
Comprehensive loss attributable to non-controlling interest		263,685			120,783
Comprehensive loss attributable to BioLife Solutions, Inc.	$	(1,226,377	)	$	(1,025,983	)

The accompanying Notes to Consolidated Financial Statements are an integral part of these consolidated financial statements

BioLife Solutions, Inc.

Consolidated Statements of Cash Flows

(unaudited)

	Three Month Period Ended March 31,
	2016			2015
Cash flows from operating activities
Net loss	$	(1,490,513	)	$	(1,152,265	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		91,791			83,646
Stock-based compensation expense		146,527			33,509
Amortization of deferred rent related to lease incentives		(31,749	)		(31,750	)
Accretion and amortization on available for sale investments		1,792			40,901

Change in operating assets and liabilities
(Increase) Decrease in
Accounts receivable, trade		(260,971	)		50,579
Inventories		(183,620	)		(277,563	)
Prepaid expenses and other current assets		17,324			72,156
Increase (Decrease) in
Accounts payable		91,907			221,046
Accrued compensation and other current liabilities		10,694			(353,077	)
Deferred rent		13,335			4,966
Net cash used in operating activities		(1,593,483	)		(1,307,852	)

Cash flows from investing activities
Sales of available-for-sale investments		1,650,000			2,100,000
Purchases of available-for-sale investments		––			(342,872	)
Costs associated with internal use software development		(552,535	)		––
Purchase of property and equipment		(26,936	)		(41,128	)
Net cash provided by investing activities		1,070,529			1,716,000

Cash flows from financing activities
Proceeds from exercise of common stock options		32,223			24,934
Deferred costs related to security issuance		(20,096	)		—
Net cash provided by financing activities		12,127			24,934

Net increase (decrease) in cash and cash equivalents		(510,827	)		433,082

Cash and cash equivalents - beginning of period		2,173,258			2,538,758

Cash and cash equivalents - end of period	$	1,662,431		$	2,971,840

Non-cash investing activity
Costs incurred for capitalized internal use software not paid as of quarter end (amounts are included in liabilities)	$	––		$	334,640

Non-cash financing activity
Option exercises for which cash not yet received as of quarter end	$	13,989		$	––
Deferred costs related to security issuance not yet paid as of quarter end	$	66,640		$	—

The accompanying Notes to Consolidated Financial Statements are an integral part of these consolidated financial statements

BioLife Solutions, Inc.

Notes to Consolidated Financial Statements

(unaudited)

1. Organization and Significant Accounting Policies

Business

BioLife Solutions, Inc. (“BioLife,” “us,” “we,” “our,” or the “Company”) is a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers. Our proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. Our biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. Additionally, for our direct, distributor, and contract customers, we perform custom formulation, fill, and finish services.

Basis of Presentation

We have prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full year. These consolidated financial statements and accompanying notes should be read in conjunction with the financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2015 on file with the SEC.

There have been no material changes to our significant accounting policies as compared to the significant accounting policies described in the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2015.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its majority-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

Concentrations of credit risk and business risk

In the three months ended March 31, 2016, we derived approximately 12% of our product revenue from one customer. In the three months ended March 31, 2015, we derived approximately 11% of our product revenue from one customer. No other customer accounted for more than 10% of revenue in the three months ended March 31, 2016 or 2015. At March 31, 2016, one customer accounted for approximately 19% of total gross accounts receivable. At December 31, 2015, three customers accounted for approximately 53% of total gross accounts receivable.

Revenue from customers located in foreign countries represented 21% of total revenue during the three months ended March 31, 2016 and 2015.

Recent Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (ASU-2016-09). The updated guidance simplifies and changes how companies account for certain aspects of share-based payment awards to employees, including accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification of certain items in the statement of cash flows. Adoption of ASU 2016-09 is required for fiscal reporting periods beginning after December 15, 2016, including interim reporting periods within those fiscal years with early adoption being permitted. The Company is currently evaluating the potential impact of the pending adoption of ASU 2016-09 on its consolidated financial statements.

In February 2016, FASB issued Accounting Standards Update No. 2016-02, Leases: Topic 842 (ASU 2016-02) that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. Under the new guidance, leases will continue to be classified as either finance or operating, with classification affecting the pattern of expense recognition in the Consolidated Statements of Operations. Lessor accounting is largely unchanged under ASU 2016-02. Adoption of ASU 2016-02 is required for fiscal reporting periods beginning after December 15, 2018, including interim reporting periods within those fiscal years with early adoption being permitted. The new standard is required to be applied with a modified retrospective approach to each prior reporting period presented with various optional practical expedients. The Company is currently evaluating the potential impact of the pending adoption of ASU 2016-02 on its consolidated financial statements.

In January 2016, the FASB issued Accounting Standards Update No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities: Topic 825 (ASU 2016-01). The updated guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. Adoption of ASU 2016-01 is required for fiscal reporting periods beginning after December 15, 2017, including interim reporting periods within those fiscal years. The Company is currently evaluating the potential impact of the pending adoption of ASU 2016-01 on its consolidated financial statements.

In November 2015, FASB issued Accounting Standards Update No. 2015-17, Balance Sheet Classification of Deferred Taxes: Topic 740 (ASU 2015-17). Current GAAP requires the deferred taxes for each jurisdiction to be presented as a net current asset or liability and net noncurrent asset or liability. This requires a jurisdiction-by-jurisdiction analysis based on the classification of the assets and liabilities to which the underlying temporary differences relate, or, in the case of loss or credit carryforwards, based on the period in which the attribute is expected to be realized. Any valuation allowance is then required to be allocated on a pro rata basis, by jurisdiction, between current and noncurrent deferred tax assets. The new guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. As a result, each jurisdiction will now only have one net noncurrent deferred tax asset or liability. The guidance does not change the existing requirement that only permits offsetting within a jurisdiction. Adoption of ASU 2015-17 is required for fiscal reporting periods beginning after December 15, 2016, including interim reporting periods within those fiscal years, and either prospective or retrospective application is permitted. Early adoption of ASU 2015-17 is permitted. At the time of adoption, all of the Company’s deferred tax assets and liabilities, along with any related valuation allowance, will be classified as noncurrent on its Consolidated Balance Sheet. The Company does not plan to early adopt ASU 2015-17.

In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory: Topic 330 (ASU 2015-11). Topic 330 currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. ASU 2015-11 requires that inventory measured using either the first-in, first-out (FIFO) or average cost method be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Adoption of ASU 2015-11 is required for fiscal reporting periods beginning after December 15, 2016, including interim reporting periods within those fiscal years. The Company does not expect adoption of ASU 2015-11 to have a material impact on its consolidated financial statements.

On May 28, 2014, FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, Topic 606, requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. Early adoption is not permitted. The updated standard becomes effective for us in the first quarter of fiscal 2018. We have not yet selected a transition method and we are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.

With the exception of the new standards discussed above, there have been no new accounting pronouncements not yet effective that have significance, or potential significance, to our Consolidated Financial Statements.

2. Accumulated Other Comprehensive Loss

The following tables show the changes in Accumulated Other Comprehensive Loss by component for the three months ended March 31, 2016:

	Three Months Ended March 31, 2016
Unrealized Loss on Investments, Beginning Balance	$	(451	)
Unrealized Gain on Investments, Current Period		451
Unrealized Loss on Investments, Ending Balance	$	––

3. Fair Value Measurement

In accordance with FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” (“ASC Topic 820”), the Company measures its cash and cash equivalents and short term investments at fair value on a recurring basis. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC Topic 820 establishes a three-tier value fair hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1 – Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than quoted prices included in Level 1 for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3 – Unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

As of March 31, 2016 and December 31, 2015, the Company does not have liabilities that are measured at fair value.

The following tables set forth the Company’s financial assets measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015, based on the three-tier fair value hierarchy:

As of March 31, 2016	Level 1		Level 2		Total
Bank deposits	$	609,247	$	—	$	609,247
Money market funds		1,053,184		—		1,053,184
Cash and cash equivalents		1,662,431		—		1,662,431
Total	$	1,662,431	$	—	$	1,662,431

As of December 31, 2015	Level 1		Level 2		Total
Bank deposits	$	440,809	$	—	$	440,809
Money market funds		1,732,449		—		1,732,449
Cash and cash equivalents		2,173,258		—		2,173,258
Corporate debt securities		1,401,453		—		1,401,453
Commercial paper		249,888		—		249,888
Short term investments		1,651,341		—		1,651,341
Total	$	3,824,599	$	—	$	3,824,599

The fair values of bank deposits, money market funds, corporate debt securities and commercial paper classified as Level 1 were derived from quoted market prices as active markets for these instruments exist. The Company has no level 2 or level 3 financial assets. The Company did not have any transfers between Level 1 and Level 2 of the fair value hierarchy during the three months ended March 31, 2016 and the twelve months ended December 31, 2015.

4. Inventory

Inventory consists of the following at March 31, 2016 and December 31, 2015:

	March 31, 2016		December 31, 2015
Raw materials	$	518,469	$	299,952
Work in progress		383,297		666,124
Finished goods		1,116,489		868,559
Total	$	2,018,255	$	1,834,635

5. Deferred Rent

Deferred rent consists of the following at March 31, 2016 and December 31, 2015:

	March 31, 2016			December 31, 2015
Landlord-funded leasehold improvements	$	1,124,790		$	1,124,790
Less accumulated amortization		(407,279	)		(375,530	)
Total		717,511			749,260
Straight line rent adjustment		178,749			165,414
Total deferred rent	$	896,260		$	914,674

During the three month periods ended March 31, 2016 and 2015, the Company recorded $31,749 and $31,750, respectively, in deferred rent amortization of these landlord funded leasehold improvements.

Straight line rent adjustment represents the difference between cash rent payments and the recognition of rent expense on a straight-line basis over the terms of the lease.

6. Share-based Compensation

Stock Options

The following is a summary of stock option activity for the three month period ended March 31, 2016, and the status of stock options outstanding at March 31, 2016:

	Three Month Period Ended
	March 31, 2016
				Wtd. Avg.
				Exercise
	Options			Price
Outstanding at beginning of year		2,555,263		$	1.80
Granted		265,000		$	1.84
Exercised		(9,985	)	$	1.40
Forfeited		(358,708	)	$	2.15
Outstanding at March 31, 2016		2,451,570		$	1.75

Stock options exercisable at March 31, 2016		1,185,030		$	1.43

As of March 31, 2016, there was $731,042 of aggregate intrinsic value of outstanding stock options, including $722,956 of aggregate intrinsic value of exercisable stock options. Intrinsic value is the total pretax intrinsic value for all “in-the-money” options (i.e., the difference between the Company’s closing stock price on the last trading day of the quarter and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all option holders exercised their options on March 31, 2016. This amount will change based on the fair market value of the Company’s stock. During the quarters ended March 31, 2016 and 2015 intrinsic value of awards exercised was $4,253 and $20,937, respectively.

The fair value of share-based payments made with stock options to employees and non-employee directors was estimated on the measurement date using the Black-Scholes model using the following weighted average assumptions (N/A for 2015 as no options were granted in that period).

	Three Month Period Ended
	March 31,
	2016			2015
Risk free interest rate		1.65	%		N/A
Dividend yield		0.0	%		N/A
Expected term (in years)		7			N/A
Volatility		75	%		N/A

The weighted average grant date fair value of options granted using these assumptions was $1.29 for the three months ended March 31, 2016.

Management applies an estimated forfeiture rate that is derived from historical employee termination data. The estimated forfeiture rate applied for the three month periods ended March 31, 2016 and 2015 was approximately 8.1% and 7.0%, respectively.

As of March 31, 2016, we had approximately $1,717,280 of unrecognized compensation expense related to unvested stock options. We expect to recognize this compensation expense over a weighted average period of approximately 3.05 years.

Restricted Stock

On March 15, 2016 the board granted 200,000 restricted stock awards under the Amended & Restated 2013 Performance Incentive Plan. The grants vested 25% immediately with the remainder vesting monthly for 36 months. The following is a summary of restricted stock activity for the three month period ended March 31, 2016, and the status of unvested restricted stock outstanding at March 31, 2016:

	Three Month Period Ended
	March 31, 2016
	Number of Restricted Shares			Grant-Date Fair Value
Outstanding at beginning of year		—		$	N/A
Granted		200,000		$	1.90
Vested		(50,000	)	$	1.90
Outstanding at March 31, 2016		150,000		$	1.90

The aggregate fair value of the awards granted during the three months ended March 31, 2016 was $380,000 which represents the market value of BioLife common stock on the date that the restricted stock awards were granted. The aggregate fair value of the restricted stock awards that vested for the three months ended March 31, 2016 was $95,000.

We recognized stock compensation expense of $98,718 for the three months ended March 31, 2016. As of March 31, 2016, there was $248,399 in unrecognized compensation costs related to restricted stock awards. We expect to recognize those costs over 2.96 years.

We recorded stock compensation expense for the three month periods ended March 31, 2016 and 2015, as follows:

	Three Month Period Ended
	March 31,
	2016			2015
Research and development costs	$	37,469		$	6,944
Sales and marketing costs		63,499			5,755
General and administrative costs		77,510			7,773
Cost of product sales		(31,951	)		13,037
Total	$	146,527		$	33,509

During the three month period ended March 31, 2016, we recorded forfeited unvested stock compensation expense in the amount of $40,317 to cost of product sales and $51,817 to general and administrative costs related to unvested stock options forfeited upon termination of certain employees.

7. Warrants

At March 31, 2016 and December 31, 2015, we had 7,195,997 warrants outstanding and exercisable with a weighted average exercise price of $4.60. The outstanding warrants have expiration dates between August 2016 and March 2021.

8. Net Loss per Common Share

Basic net loss per common share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated using the weighted average number of common shares outstanding plus dilutive common stock equivalents outstanding during the period. Common stock equivalents are excluded for the three month periods ended March 31, 2016 and 2015, since the effect is anti-dilutive due to the Company’s net losses. Common stock equivalents include stock options, warrants and unvested restricted stock.

Basic weighted average common shares outstanding, and the potentially dilutive securities excluded from loss per share computations because they are anti-dilutive, are as follows as of March 31, 2016 and 2015, respectively:

	Three Month Period Ended March 31,
	2016		2015
Basic and diluted weighted average common stock shares outstanding		12,457,858		12,100,588
Potentially dilutive securities excluded from loss per share computations:
Common stock options		2,451,570		1,368,528
Common stock purchase warrants		7,195,997		7,428,141
Restricted stock unvested		150,000		—

9. Commitments & Contingencies

Leases

We lease approximately 30,000 square feet in our Bothell, Washington headquarters. The term of our lease continues until July 31, 2021 with two options to extend the term of the lease, each of which is for an additional period of five years, with the first extension term commencing, if at all, on August 1, 2021, and the second extension term commencing, if at all, immediately following the expiration of the first extension term. In accordance with the amended lease agreement, our monthly base rent is approximately $59,700, with scheduled annual increases each August and again in October for the most recent amendment. We are also required to pay an amount equal to the Company’s proportionate share of certain taxes and operating expenses.

Employment agreements

We have employment agreements with the Chief Executive Officer, Chief Financial Officer, Chief Technology Officer, Vice President of Operations, Vice President, Marketing and Vice President, Global Sales. None of these employment agreements is for a definitive period, but rather each will continue indefinitely until terminated in accordance with its terms. The agreements provide for a base annual salary, payable in monthly (or shorter) installments. In addition, the agreement with the Chief Executive Officer provides for incentive bonuses at the discretion of the Board of Directors. Under certain conditions and for certain of these officers, we may be required to pay additional amounts upon terminating the officer or upon the officer resigning for good reason.

biologistex

Our biologistex joint venture committed to purchase approximately $2.4 million in Smart Containers from SAVSU. As of March 31, 2016, the purchase commitment is $2.1 million.

Litigation

From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none of which are currently material to the Company’s business.

10. Subsequent Events

Credit Facility

On May 12, 2016 we entered into a $4 million credit facility agreement with our largest shareholder WAVI Holding AG (“WAVI”). The agreement calls for WAVI to provide four $1 million tranches at specified times throughout the next 12 months. The related promissory note matures on June 1, 2017, and is unsecured, but senior to any existing debt. In addition, we have agreed not to pledge or secure our assets for any other obligations outside the normal course of our business. The promissory note carries an annual interest rate of 10% and WAVI was issued 5 year warrants to purchase 550,000 shares of common stock at a fixed exercise price of $1.75 per share.

MNX Relationship

In April, we formed a relationship with MNX Global Logistics, a specialty courier offering door to door, same day and next flight out managed logistics in order to increase the attractiveness of our product offering by offering value-added ancillary logistics services for time and temperature sensitive biologic materials.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements”. These forward-looking statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. These statements are based on current expectations of future events. Such statements include, but are not limited to, statements about future financial and operating results, plans, objectives, expectations and intentions, costs and expenses, interest rates, outcome of contingencies, financial condition, results of operations, liquidity, business strategies, cost savings, objectives of management and other statements that are not historical facts. You can find many of these statements by looking for words like “believes,” “expects,” “anticipates,” “estimates,” “may,” “should,” “will,” “could,” “plan,” “intend,” or similar expressions in this Quarterly Report on Form 10-Q. We intend that such forward-looking statements be subject to the safe harbors created thereby. Examples of these forward-looking statements include, but are not limited to:

anticipated product developments, regulatory filings and related requirements;

timing and amount of future contractual payments, product revenue and operating expenses;

market acceptance of our products and the estimated potential size of these markets; and

projections regarding liquidity, capital requirements and the terms of any financing agreements.

These forward-looking statements are based on the current beliefs and expectations of our management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results may differ materially from current expectations and projections. These risks and uncertainties include those factors described in greater detail in the risk factors disclosed in our Form 10-K for the fiscal year ended December 31, 2015 filed with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those anticipated in these forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q or, in the case of documents referred to or incorporated by reference, the date of those documents.

All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S. securities law. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Overview

Management’s discussion and analysis provides additional insight into the Company and is provided as a supplement to, and should be read in conjunction with, our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed with the SEC.

We were incorporated in Delaware in 1987 under the name Trans Time Medical Products, Inc. In 2002, the Company, then known as Cryomedical Sciences, Inc., and engaged in manufacturing and marketing cryosurgical products, completed a merger with our wholly-owned subsidiary, BioLife Solutions, Inc., which was engaged as a developer and marketer of biopreservation media products for cells and tissues. Following the merger, we changed our name to BioLife Solutions, Inc. We have one majority-owned subsidiary, biologistex CCM, LLC, a Delaware limited liability company.

Our proprietary, clinical grade HypoThermosol® FRS and CryoStor® biopreservation media products are marketed to the regenerative medicine, biobanking and drug discovery markets, including hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, hair transplant centers, and suppliers of cells to the drug discovery, toxicology testing and diagnostic markets. All of our biopreservation media products are serum-free and protein-free, fully defined, and are manufactured under current Good Manufacturing Practices (cGMP) using United States Pharmacopia (USP)/Multicompendial or the highest available grade components.

Our patented biopreservation media products are formulated to reduce preservation-induced, delayed-onset cell damage and death. Our platform enabling technology provides our customers significant shelf life extension of biologic source material and final cell products, and also greatly improved post-preservation cell, tissue, and organ viability and function.

The discoveries made by our scientists and consultants relate to how cells, tissues, and organs respond to the stress of hypothermic storage, cryopreservation, and the thawing process. These discoveries enabled the formulation of innovative biopreservation media products that protect biologic material from preservation-related cellular injury, much of which is not apparent immediately after return to normothermic body temperature. Our product formulations have demonstrated notable reduction in apoptotic (programmed) and necrotic (pathologic) cell death mechanisms and are enabling the clinical and commercial development of dozens of innovative regenerative medicine products.

On September 29, 2014, we entered into a limited liability company agreement with SAVSU Technologies, LLC, a Delaware limited liability company, to create a 20-year joint venture for the purpose of acquiring, developing, maintaining, owning, operating, marketing and selling an integrated platform of a cloud-based information service and precision thermal shipping products. The evo™ line is our new line of “smart shippers” designed for the shipment of materials, which must be maintained frozen, at 2-8˚C and/or controlled room temperature temperatures and where near real time monitoring of temperature, location, and payload status information is necessary. A sophisticated electronics package embedded in the evo provides streaming data to the biologistex web-based application; where real time shipment status, history, and reports can be generated. Designed for small volume shipments; it fills a critical need in chain-of-custody scenarios for temperature sensitive shipments of cells, tissues, and other cell based products.

Highlights for the First Quarter of 2016

Biopreservation media products revenue was $1.9 million in the first quarter of 2016, an increase of 25% over the same period in 2015. First quarter revenue growth drivers include 38% higher direct sales to our regenerative medicine customers compared to the same period in 2015 and higher sales through our distribution network. Sales to our US and international distributors also grew over 45% compared to the same period in 2015.

Gross margin in the first quarter of 2016 was 58%, compared to 59% in the first quarter of 2015. The margin declined slightly due to an underutilization adjustment in the current quarter, which was offset by forfeited amounts of unvested stock compensation expense.

For the three months ended March 31, 2016, consolidated net loss was $1.5 million and net loss attributable to BioLife was $1.2 million. This compared to a consolidated net loss of $1.2 million in the first quarter of 2015. The increase in the loss is primarily the result of increased headcount and severance payouts to former executive employees.

Internally developed significant functionality to the biologistex cloud based platform, including ability to integrate third party application program interface with third party logistic providers.

To further round out our offering of evo and biologistex, ALL SEASON™ Cold Packs and Payload Carriers for the evo were introduced as the newest members of the product family. To provide evidence of the performance of evo and biologistex, we also completed further validation testing and reporting on the thermal performance of the evo Smart Shipper under extreme conditions and simulated inappropriate packout conditions and also data integrity in our biologistex SaaS.

Customer Adoption: Management believes that BioLife products are now embedded in over 215 pre-clinical validation projects and human clinical trials for new cell and tissue-based regenerative medicine products and therapies.

Results of Operations

Our revenue, results of operations and cash balances are likely to fluctuate significantly from quarter-to-quarter. These fluctuations are due to a number of factors, specifically the progress of our customers’ clinical trials, where the pace of enrollment affects customer orders for our products. The majority of our net sales come from a relatively small number of customers and a limited number of market sectors. Each of these sectors is subject to macroeconomic conditions as well as trends and conditions that are sector specific. Any weakness in the market sectors in which our customers are concentrated could affect our business and results of operations.

Comparison of Results of Operations for the Three Month Periods Ended March 31, 2016 and 2015

Percentage comparisons have been omitted within the following table where they are not considered meaningful.

Revenue and Gross Margin

	Three Month Period Ended
	March 31,
	2016			2015			% Change
Revenue:
Biopreservation media product sales	$	1,852,017		$	1,477,176			25	%
Contract manufacturing services		—			23,546			(100	)%
Total revenue		1,852,017			1,500,722			23	%

Cost of sales		771,005			618,099			25	%
Gross profit	$	1,081,012		$	882,623			22	%
Gross margin %		58	%		59	%

Biopreservation Media Product Sales. Our core products are sold through both direct and indirect channels to customers in the regenerative medicine, biobanking and drug discovery markets. Sales of our core proprietary products in the three months ended March 31, 2016 increased 25% compared to the same period in 2015, due primarily to an increase in selling price per liter sold due to change in product mix sold and customized biopreservation media formulations. Proprietary revenue growth was driven by a 38% year over year increase from customers in the regenerative medicine segment and 45% increase in our US and international distributors. We expect to see continued growth in adoption and use of our proprietary biopreservation media products, and estimate 20% - 30% growth in core product revenue for the full year over 2015.

Contract Manufacturing Services. We had no contract manufacturing revenue in the first quarter of 2016. We do not expect to have any contract manufacturing revenue in the near term. In 2015, the contract manufacturing revenue was the result of process validation work performed for one customer and sales of certain raw materials related to this customer.

Cost of Sales. Cost of sales consists of raw materials, labor and overhead expenses. Cost of sales in the three months ended March 31, 2016 increased compared to the same period in 2015 due to increased sales of our biopreservation media products and an underutilization adjustment which was partially offset by a reduction in stock-based compensation related to forfeited options from a former employee.

Gross Margin. Gross margin as a percentage of revenue was 58% in the three months ended March 31, 2016 compared to 59% in the three months ended March 31, 2015. For the full year, we expect gross margin to be in the range of 55% to 65% on core biopreservation media products.

Revenue Concentration. In the three months ended March 31, 2016, we derived approximately 12% of our product revenue from one customer. In the three months ended March 31, 2015, we derived approximately 11% of our product revenue from one customer. No other customer accounted for more than 10% of revenue in the three months ended March 31, 2016 or 2015.

Operating Expenses

Our operating expenses for the three month periods ended March 31, 2016 and 2015 were:

	Three Month Period Ended
	March 31,
	2016			2015			% Change
Operating Expenses:
Research and development	$	504,239		$	322,165			57	%
Sales and marketing		733,913			500,255			47	%
General and administrative		1,335,292			1,220,705			9	%
Operating Expenses		2,573,444			2,043,125			26	%
% of revenue		139	%		136	%

Research and Development. Research and development expenses consist primarily of salaries and other personnel-related expenses, consulting and other outside services, laboratory supplies, and other costs. We expense all research and development costs as incurred, with the exception of the costs associated with the development of customized internal-use software systems, which are capitalized. Research and development expenses for the three months ended March 31, 2016 increased compared to the three months ended March 31, 2015, due primarily to expensed costs related to maintenance of customized internal-use software and costs associated with new media and biologistex product development.

Sales and Marketing. Sales and marketing expenses consist primarily of salaries and other personnel-related expenses, consulting, trade shows and advertising. The increase in the three months ended March 31, 2016 compared to the same period in 2015 was due primarily to higher personnel costs, with the addition of personnel hired throughout 2015 and costs related to the initial marketing activities of our biologistex joint venture.

General and Administrative Expenses. General and administrative expenses consist primarily of personnel-related expenses, non-cash stock-based compensation for administrative personnel and members of the board of directors, professional fees, such as accounting and legal, corporate insurance, and in 2015, participation fees to SAVSU related to the biologistex joint venture. The increases in general and administrative expenses in the three months ended March 31, 2016 were due primarily to higher personnel costs, including severance expense for two former executives, and stock-based compensation related to new issuances of options and restricted stock grants in the first quarter of 2016, partially offset by no SAVSU participation fees in 2016.

Other Income

Interest Income. The reduction in interest income in the three months ended March 31, 2016 compared to the same period in 2015 is due to the lower average short-term investments balance in 2016 compared to 2015.

Liquidity and Capital Resources

On March 31, 2016, we had $1.7 million in cash and cash equivalents, compared to cash, cash equivalents and short-term investments of $3.8 million at December 31, 2015.

We have entered into a $4 million credit facility with our largest shareholder and believe this amount, when combined with cash from operations, is sufficient to fund our working capital requirements for at least the next 12 months and allow us to reach positive cash flow from operations in 2017.

We are continuously monitoring and evaluating opportunities to strengthen our balance sheet and competitive position over the long term. These actions may include acquisitions or other strategic transactions that we believe would generate significant advantages and substantially strengthen our business. The consideration we pay in such transactions may include, among other things, shares of our common stock, other equity or debt securities of our Company or cash. We may elect to seek debt or equity financing in anticipation of, or in connection with, such transactions or to fund or invest in any operations acquired thereby.

Net Cash Used In Operating Activities

During the three months ended March 31, 2016, net cash used in operating activities was $1.6 million compared to $1.3 million for the three months ended March 31, 2015. Cash used in operating activities increased primarily due to the use of cash to fund a higher net loss, including the payment of certain severance expenses and cash used by changes in operating assets and liabilities during the period ended March 31, 2016 compared to the same period in 2015.

Net Cash Provided by Investing Activities

Net cash provided by investing activities totaled $1.1 million during the three months ended March 31, 2016 compared to $1.7 million for the three months ended March 31, 2015, which was the result of sales and maturities of short term investments, net of purchases of short term investments and purchases of internal use software and equipment during the quarter.

Net Cash Provided by Financing Activities

Net cash provided by financing activities totaled $12,127 during the three months ended March 31, 2016, compared to $24,934 net cash provided by financing activities during the three months ended March 31, 2015. Net cash provided by financing activities in the three months ended March 31, 2016 and 2015 was the result of proceeds received from employee stock option exercises.

Off-Balance Sheet Arrangements

As of March 31, 2016, we did not have any off-balance sheet arrangements.

Critical Accounting Policies and Significant Judgments and Estimates

Management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements as well as reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate estimates, including, but not limited to those related to accounts receivable allowances, determination of fair value of share-based compensation, contingencies, income taxes, useful lives and impairment of intangible assets and internal use software, and expense accruals. We base our estimates on historical experience and on other factors that we believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.

Our critical accounting policies and estimates have not changed significantly from those policies and estimates disclosed under the heading “Critical Accounting Policies and Significant Judgments and Estimates” in Part II, Item 7, “Management’s Discussion and Analysis of Financial Conditions and Results of Operations” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the SEC.

Contractual Obligations

We previously disclosed certain contractual obligations and contingencies and commitments relevant to us within the financial statements and Management Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC on February 25, 2016. There have been no significant changes to these obligations in the three months ended March 31, 2016. For more information regarding our current contingencies and commitments, see note 10 to the consolidated financial statements included above.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures. We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer as appropriate, to allow timely decisions regarding required disclosure. During the quarter ended March 31, 2016, we carried out an evaluation, under the supervision and with the participation of our management, including the chief executive officer and chief financial officer, as required by the rules and regulations under the Exchange Act, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of March 31, 2016, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting. There have been no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2016 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Limitations on Effectiveness of Control. Our management, including our chief executive officer and chief financial officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected.

PART II: Other Information

Item 5. Other Information.

On May 12, 2016, we entered into a commitment letter (the “Commitment Letter”) with WAVI, pursuant to which WAVI has agreed to make a series of four $1 million advances on June 1, 2016, September 1, 2016, December 1, 2016 and March 1, 2017 (each, an “Advance”). Prior to entering into the commitment letter, we understand that WAVI was the beneficial owner of 3,604,646 outstanding shares of our common stock and warrants exercisable to purchase an additional 1,777,211 shares of our common stock. WAVI is controlled by Walter Villiger, who holds also warrants exercisable for 142,857 shares of our common stock.

Pursuant to the Commitment Letter, on May 12, 2016 we entered into a promissory note (the “Note”) in favor of WAVI whereby we agreed to pay WAVI the principal amount of all Advances under the Note, plus interest. The Note is unsecured, carries an annual interest rate of 10% and matures on June 1, 2017. WAVI is not obligated to pay any Advance if an event of default, as defined in the Note, has occurred or is occurring. The Note provides that we will not permit any liens on our assets, subject to certain exceptions.

As partial consideration for WAVI entering into the Commitment Letter, we issued WAVI a common stock purchase warrant (the “Warrant”) exercisable to purchase up to 550,000 shares of our common stock at an exercise price of $1.75 per share. The exercise price is subject to adjustment in the case of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our common stock. The Warrant does not include any beneficial ownership limitation. The Warrant expires on May 12, 2021. The Warrant issued to WAVI has not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), and was issued to WAVI, which is a non-U.S. person, in an offshore transaction relying on the exemption from registration provided by Regulation S under the Securities Act.

The foregoing descriptions of the Commitment Letter, the Note and the Warrant do not purport to be complete descriptions of the rights and obligations of the parties thereunder and are qualified in their entirety by reference to the Commitment Letter, the Note and the Warrant, which are filed as Exhibits 10.6, 10.7 and 10.8, respectively, to this Quarterly Report on Form 10-Q.

Item 6. Exhibits

See accompanying Index to Exhibits included after the signature page of this report for a list of exhibits filed or furnished with this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOLIFE SOLUTIONS, INC.


Dated: May 16, 2016	/s/ Roderick de Greef
	Roderick de Greef
	Chief Financial Officer (Duly authorized officer and principal financial and accounting officer)

BioLife Solutions, Inc.

INDEX TO EXHIBITS

Exhibit No.		Description

10.1		First Amendment to Employment Agreement dated February 25, 2016 between the Company and Daphne Taylor

10.2		Employment Agreement effective April 13, 2016 between the Company and Karen Foster

10.3		Employment Agreement dated May 3, 2016 between the Company and Roderick de Greef

10.4		Form of Restricted Stock Purchase Agreement pursuant to the Amended & Restated 2013 Performance Incentive Plan

10.5		Form of Stock Option Agreement pursuant to the Amended & Restated 2013 Performance Incentive Plan

10.6		Commitment Letter dated May 12, 2016 between the Company and WAVI Holding AG

10.7		Common Stock Purchase Warrant issued to WAVI Holding AG

10.8		Promissory Note made by the Company in favor of WAVI Holding AG

31.1		Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

EX-10.1 2 v439570_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

This First Amendment to Employment Agreement (“Amendment”), effective as of February 25, 2016, is made by and between BioLife Solutions Inc. (“BioLife Solutions” or the “Company”), and Daphne Taylor (“Executive”) and amends that certain employment agreement, dated February 19, 2015 (the “Employment Agreement”), between BioLife Solutions and Executive.

WHEREAS, the parties previously entered into the Employment Agreement to provide for Executive’s services as the Chief Financial Officer of the Company;

WHEREAS, Executive and the Company desire to amend Executive’s Employment Agreement on the terms set forth herein;

NOW, THEREFORE, in consideration of the representations, warranties, covenants and agreements contained in this Amendment and other good and valuable consideration, the sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

1. Nothwithstanding any other provisions in the Employment Agreement to the contrary, if Executive voluntarily resigns from all positions, offices, and corresponding duties and responsibilities in all capacities with the Company and biologistex CCM, LLC, effective as of the date of this Amendment, Employer will pay Executive:

a.	(i) her salary through the date of termination, (ii) for any unused vacation time, and (iii) for any unreimbursed business expenses that are subject to reimbursement under the company’s then current policy on business expenses.
b.	severance pay of six (6) months’ worth of Executive’s salary at the rate in effect on the termination date, payable in the form of a lump sum.

Such payments will be subject to all appropriate deductions and withholdings. Upon resignation, Executive will have no rights to any unvested benefits or any other compensation.

Executive shall only be entitled to such severance pay if, within thirty (30) days following the date of resignation, both the Company and Executive have signed (and then Executive does not rescind, as may be permitted by law) a general release of claims in a form acceptable to Employer.

2. The Employment Agreement remains unchanged except as set forth in this Amendment.

3. To the extent there is any conflict or any inconsistency between this Amendment and the Employment Agreement, the provisions within this Amendment control.

IN WITNESS WHEREOF, the parties have duly signed and delivered this First Amendment to the Employment Agreement as of the day and year first above written.

BioLife Solutions Inc.

/s/ Michael Rice	/s/ Daphne Taylor
By: Michael Rice	Daphne Taylor
Its: President & Chief Executive Officer

EX-10.2 3 v439570_ex10-2.htm EXHIBIT 10.2

Exhibit 10.2

EXECUTIVE EMPLOYMENT AGREEMENT

THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made between BioLife Solutions Inc., a Delaware corporation (“Employer” or the “Company”), and Karen Foster (“Executive”). Executive and the Company are sometimes referred to herein as the “Parties.” The effective date of this Agreement is April 13, 2016, Executive’s first day of employment with the Company.

RECITALS

A. Employer is in the business (the “Business”) of manufacturing and marketing proprietary biopreservation media for cells, tissues, and organs and smart shippers and a cloud hosted application for cold chain logistics of time and temperature sensitive biologic materials.

B. Employer desires to obtain the services of Executive, in which capacity Executive has access to Employer’s Confidential Information (as hereinafter defined), and to obtain assurance that Executive will protect Employer’s Confidential Information and will not compete with Employer or solicit its customers or its other employees during the term of employment and for a reasonable period of time after termination of employment pursuant to this Agreement, and Executive is willing to agree to these terms.

C. Executive desires to be assured of the salary and other benefits provided for in this Agreement.

AGREEMENT

NOW, THEREFORE, in consideration of the mutual covenants herein contained, and other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the parties agree as follows:

1. Employment.

a. Employer hereby employs Executive, and Executive agrees to be employed as Vice President, Operations, in accordance with the terms and conditions set forth in this Agreement. Changes may be made from time to time by Employer / the Board in its sole discretion to the duties, authorities, reporting relationships and title of Executive.

b. Executive will devote full time, attention, and best efforts to achieving the purposes and discharging the responsibilities of the position of Vice President, Operations. Executive will comply with all rules, policies and procedures of Employer as modified from time to time, including without limitation, rules and procedures set forth in the Employer’s employee handbook, supervisor’s manuals and operating manuals. Executive will perform all of Executive’s responsibilities in compliance with all applicable laws and will ensure that the operations that Executive manages are in compliance with all applicable laws. During Executive’s employment, Executive will not engage in any other business activity which, in the reasonable judgment of the Employer, conflicts with the duties of Executive under this Agreement, whether or not such activity is pursued for gain, profit or other pecuniary advantage.

c. Nothing herein shall preclude Executive from: (1) continuing to serve on the board of directors or trustees of any business corporation or any charitable organization on which she currently serves and which is identified on Exhibit A hereto, or (2) subject to the prior approval of the Board, appointment to any additional directorships or trusteeships, or (3) serving in an advisory role for other business entities, provided in each case, and in the aggregate, that such activities do not interfere with the performance of Executive’s duties hereunder or conflict with Section 9 of this Agreement.

2. Term of Employment. The term of employment (“Term”) will not be for a definite period, but rather continue indefinitely until terminated in accordance with the terms and conditions of this Agreement.

3. Compensation. For the duration of Executive’s employment hereunder, the Executive will be entitled to compensation which will be computed and paid pursuant to the following subparagraphs.

a. Base Salary. Employer will pay to Executive a base salary (“Base Salary”) at an annual rate of two hundred eighty five thousand Dollars ($285,000.00), payable in such installments (but in no event less than monthly), subject to withholdings and deductions as required or permitted by law, as is Employer’s policy with respect to other employees. Executive’s Base Salary will be reviewed periodically by the Board of Directors of Employer during the term of Executive’s employment and may be adjusted in the sole discretion of the Board of Directors based on such review, but will not be reduced by Employer unless a material adverse change in the financial condition or operations of Employer has occurred or unless Executive’s responsibilities are altered to reflect less responsibility.

4. Other Benefits.

a. Certain Benefits. Executive will be eligible to participate in all employee benefit programs established by Employer that are applicable to management personnel such as medical, pension, disability and life insurance plans on a basis commensurate with Executive’s position and in accordance with Employer’s policies from time to time, but nothing herein shall require the adoption or maintenance of any such plan.

b. Vacations, Holidays and Expenses. Executive will be provided accrued paid vacation of three (3) weeks each calendar year, which shall be the maximum number of days Executive may accrue at any time, and which shall be taken at such times as are consistent with Executive’s responsibilities hereunder. Executive will be provided such holidays and vacation as Executive makes available to its management level employees generally. Employer will reimburse Executive in accordance with company policies and procedures for reasonable expenses necessarily incurred in the performance of duties hereunder against appropriate receipts and vouchers indicating the specific business purpose for each such expenditure. In no case shall any reimbursement be made later than December 31 of the year following the calendar year in which such expense is incurred.

c. Right of Set-off. By accepting this Agreement, Executive consents to a deduction from any amounts Employer owes Executive from time to time (including amounts owed to Executive as wages or other compensation, fringe benefits, or vacation pay, as well as any other amounts owed to Executive by Employer), to the extent of the amounts Executive owes to Employer. Whether or not Employer elects to make any set-off in whole or in part, if Employer does not recover by means of set-off the full amount Executive owes it, calculated as set forth above, Executive agrees to pay immediately the unpaid balance to Employer.

5. Termination Or Discharge By Employer.

a. For Cause. Employer will have the right to immediately terminate Executive’s services and this Agreement for Cause. “Cause” means the Employer’s belief that any of the following has occurred:

(i) any breach of this Agreement by Executive, including, without limitation, breach of Executive’s covenants in Sections 9, 10, 11 and 12;

(ii) any failure to perform assigned job responsibilities that continues unremedied for a period of ten (10) days after written notice to Executive by Employer;

(iii) Executive’s malfeasance or misconduct in connection with Executive’s duties hereunder or any act or omission of Executive which is materially injurious to the financial condition or business reputation of the Company or any of its subsidiaries or affiliates,

(iv) commission of a felony or misdemeanor or failure to contest prosecution for a felony or misdemeanor;

(v) the Employer’s reasonable belief that Executive engaged in a violation of any statute, rule or regulation, any of which in the judgment of Employer is harmful to the Business or to Employer’s reputation;

(vi) the Employer’s reasonable belief that Executive engaged in unethical practices, dishonesty or disloyalty;

(vii) or any reason that would constitute Cause under the laws the State of Washington.

Upon termination of Executive’s employment hereunder for Cause, the Company shall pay the Executive no later than fourteen (14) days from the termination date in a lump sum: (i) her salary through the date of termination, (ii) for any unused vacation time, and (iii) for any unreimbursed business expenses that are subject to reimbursement under Employer’s then current policy on business expenses. Executive will have no rights to any unvested benefits or any other compensation or payments after the termination date.

b. Due to Death or Disability. Employer will have the right to immediately terminate Executive’s services and this Agreement due to death or disability. For purposes of this Agreement, “disability” means the incapacity or inability of Executive, whether due to accident, sickness or otherwise, as determined by a medical doctor acceptable to the Board of Directors of Employer and confirmed in writing by such doctor, to perform the essential functions of Executive’s position under this Agreement, with or without reasonable accommodation (provided that no accommodation that imposes undue hardship on Employer will be required) for a period of sixty (60) consecutive days or for an aggregate of ninety (90) days during any period of twelve (12) months, or such longer period as may be required under disability law.

Upon termination of Executive’s employment hereunder due to death or disability, the Company shall pay the Executive no later than sixty (60) days from the termination date in a lump sum: (i) her salary through the date of termination, (ii) for any unused vacation time, and (iii) for any unreimbursed business expenses that are subject to reimbursement under Employer’s then current policy on business expenses. Upon termination of Executive’s employment hereunder due to death or disability, Executive or Executive’s estate (as the case may be) shall be entitled to receive any vested benefits required to be paid by law and any vested compensation required to be paid by law. Executive and Executive’s estate will have no rights to any unvested benefits or any other compensation or payments after the termination date.

c. Without Cause. Employer may terminate Executive’s employment under this Agreement without cause and without advance notice; provided, however, that Employer will pay (unless subparagraph 5(d) of this Agreement applies, in which case the provisions therein shall govern), no later than sixty (60) days from the termination date in a lump sum:

(i)

(i) her salary through the date of termination, (ii) for any unused vacation time, and (iii) for any unreimbursed business expenses that are subject to reimbursement under Employer’s then current policy on business expenses.

(ii)

severance pay of (i) three (3) months’ worth of Executive’s salary at the rate in effect on the termination date. Such payments will be subject to all appropriate deductions and withholdings. Upon termination, Executive will have no rights to any unvested benefits or any other compensation.

Executive shall only be entitled to such severance pay if, within thirty (30) days following the date of termination, both Employer and Executive have signed (and then Executive does not rescind, as may be permitted by law) a mutual general release of claims in a form mutually acceptable to both parties (provided, however, that such release of claims shall only require each party to release the other party from claims relating directly to Executive’s employment and the termination thereof, and shall not require Executive to release claims relating to vested employee benefits or relating to other matters, including, but not limited to, claims relating to her status as a shareholder of the Company.

d. Change in Control. For purposes of this Agreement, Change in Control shall mean the occurrence of any of the following events:

(i) Any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) is or becomes the “Beneficial Owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company’s then outstanding voting securities without the approval of the Board of Directors of the Company, unless the Board of Directors specifically designates such acquisition to be a change of control; or

(ii) A merger or consolidation of the Company whether or not approved by the Board of Directors of the Company, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation, or the shareholders of the Company approve a plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets.

(iii) Employer may terminate Executive’s employment under this Agreement upon or within 90 days following a Change in Control without advance notice; provided, however, that Employer will pay, no later than sixty (60) days from the termination date in a lump sum:

(a)

(b)

as severance pay, twelve (12) months’ worth of Executive’s salary at the rate in effect on the termination date.

Such payments will be subject to all appropriate deductions and withholdings. Upon termination, Executive will have no rights to any unvested benefits or any other compensation.

(ii) Executive shall only be entitled to such severance pay if, within thirty (30) days following the date of termination, both Employer and Executive have signed (and then Executive does not rescind, as may be permitted by law) a mutual general release of claims in a form mutually acceptable to both parties (provided, however, that such release of claims shall only require each party to release the other party from claims relating directly to Executive’s employment and the termination thereof, and shall not require Executive to release claims relating to vested employee benefits or relating to other matters, including, but not limited to, claims relating to her status as a shareholder of the Company.

7. Termination By Executive for Good Reason. Executive’s employment pursuant to this Agreement shall terminate in the event Executive shall determine that there is “Good Reason” to terminate her employment, which shall mean the following:

a. Employer’s material breach of the terms of this Agreement or any other written agreement between Executive and Employer;

b. the assignment to Executive of any duties that are substantially inconsistent with or materially diminish Executive’s position prior to execution of this Agreement;

c. a material reduction of Executive’s salary, other than as a result of a general salary reduction affecting substantially all Company employees; or

d. any failure by the Company to obtain the assumption of this Agreement by any successor or assign of the Company;

Provided that Executive has provided with notice of the existence of a condition giving rise to “Good Reason” to terminate within ninety (90) days following the initial existence of such a condition, Employer shall have thirty (30) days to cure any such alleged breach, assignment, reduction or requirement under Subsections a, b, c and d, above, after Executive provides Employer written notice of the actions or omissions constituting such breach, assignment, reduction or requirement.

If Executive resigns her employment for Good Reason, Executive shall be paid no later than sixty (60) days from the termination date in a lump sum:

8. Return of Company Property. Upon termination of this Agreement or upon request of the Company, Executive shall deliver to the Corporation all property, documents and materials pertaining to the Company’s business including, but not limited to, memoranda, notes, records, drawings, manuals, disks, copies, representations, extracts, summaries and analyses, all inventory, demonstration units, and any other property, documents or media of the Corporation, and all equipment belonging to the company, including but not limited to corporate cards, access cards, office keys, office equipment, laptop and desktop computers, cell phones and other wireless devices, thumb drives, zip drives and all other media storage devices.

9. Covenant Not To Compete. During Executive’s employment by Employer and for a period expiring one (1) year after the termination of Executive’s employment for any reason, Executive covenants and agrees that Executive will not:

a. Directly, indirectly, or otherwise, own, manage, operate, control, serve as a consultant to, be employed by, participate in, or be connected, in any manner, with the ownership, management, operation or control of any business that competes with the Business or that competes with Employer or any of its affiliates or that is engaged in any type of business which, at any time during Executive’s employment with Employer, Employer or any of its affiliates planned to develop;

b. Hire, offer to hire, entice away or in any other manner persuade or attempt to persuade any officer, employee or agent of Employer or any of its affiliates to alter or discontinue a relationship with Employer or to do any act that is inconsistent with the interests of Employer or any of its affiliates;

c. Directly or indirectly solicit, divert, take away or attempt to solicit, divert or take away any customers of Employer or any of its affiliates; or

d. Directly or indirectly solicit, divert, or in any other manner persuade or attempt to persuade any supplier of Employer or any of its affiliates to alter or discontinue its relationship with Employer or any of its affiliates.

For the purposes of this Section 9, businesses that are deemed to compete with Employer include, without limitation, businesses engaged in manufacturing and marketing biopreservation media for cells, tissues, and organs and cold chain management products and services for time and/or temperature sensitive biologic material. The geographic scope of the prohibitions in this Section 9 shall be any city, town or county in which the Company conducts or does any business as of or within one (1) year of Executive’s last day of employment with the Company. Notwithstanding Executive’s obligations under this Section 9, Executive will be entitled to own, as a passive investor, up to five percent (5%) of any publicly traded company without violating this provision.

Employer and Executive agree that: this provision does not impose an undue hardship on Executive and is not injurious to the public; that this provision is necessary to protect the business of Employer and its affiliates; the nature of Executive’s responsibilities with Employer under this Agreement require Executive to have access to confidential information which is valuable and confidential to all of the Business; the scope of this Section 9 is reasonable in terms of length of time and geographic scope; and adequate consideration supports this Section 9, including consideration herein.

10. Confidential Information. Executive recognizes that Employer’s business and continued success depend upon the use and protection of confidential and proprietary business information, including, without limitation, the information and technology developed by or available through licenses to Employer, to which Executive has access (all such information being “Confidential Information”). For purposes of this Agreement, the phrase “Confidential Information” includes, for Employer and its current or future subsidiaries and affiliates, without limitation, and whether or not specifically designated as confidential or proprietary: all business plans and marketing strategies; information concerning existing and prospective markets and customers; financial information; information concerning the development of new products and services; information concerning any personnel of Employer (including, without limitation, skills and compensation information); intellectual property; and technical and non-technical data related to software programs, designs, specifications, compilations, inventions, improvements, methods, processes, procedures and techniques; provided, however, that the phrase does not include information that (a) was lawfully in Executive’s possession prior to disclosure of such information by Employer; (b) was, or at any time becomes, available in the public domain other than through a violation of this Agreement; (c) is documented by Executive as having been developed by Executive outside the scope of Executive’s employment and independently; or (d) is furnished to Executive by a third party not under an obligation of confidentiality to Employer. Executive agrees that during Executive’s employment and after termination of employment irrespective of cause, Executive will use Confidential Information only (i) while employed by the Company, in the business of and for the benefit of the Company, or (ii) when required to do so by a court of competent jurisdiction, by any governmental agency having supervisory authority over the business of the Company, or by any administrative body or legislative body (including a committee thereof) with jurisdiction to order Executive to divulge, disclose or make accessible such information, and then only after providing written notice to Employer that such a demand has been made. Executive’s obligation under this Agreement is in addition to any obligations Executive has under state or federal law. Executive agrees to deliver to Employer immediately upon termination of Executive’s employment, or at any time Employer so requests, all tangible items containing any Confidential Information (including, without limitation, all memoranda, photographs, records, reports, manuals, drawings, blueprints, prototypes, notes taken by or provided to Executive, and any other documents or items of a confidential nature belonging to Employer), together with all copies of such material in Executive’s possession or control. Executive agrees that in the course of Executive’s employment with Employer, Executive will not violate in any way the rights that any entity has with regard to trade secrets or proprietary or confidential information. Executive’s obligations under this Section 10 are indefinite in term and shall survive the termination of this Agreement.

11. Work Product and Copyrights. Executive agrees that all right, title and interest in and to the materials resulting from the performance of Executive’s duties at Employer and all copies thereof, including works in progress, in whatever media, (the “Work”), will be and remain in Employer upon their creation. Executive will mark all Work with Employer’s copyright or other proprietary notice as directed by Employer. Executive further agrees:

a. To the extent that any portion of the Work constitutes a work protectable under the copyright laws of the United States (the “Copyright Law”), that all such Work will be considered a “work made for hire” as such term is used and defined in the Copyright Law, and that Employer will be considered the “author” of such portion of the Work and the sole and exclusive owner throughout the world of copyright therein; and

b. If any portion of the Work does not qualify as a “work made for hire” as such term is used and defined in the Copyright Law, that Executive hereby assigns and agrees to assign to Employer, without further consideration, all right, title and interest in and to such Work or in any such portion thereof and any copyright therein and further agrees to execute and deliver to Employer, upon request, appropriate assignments of such Work and copyright therein and such other documents and instruments as Employer may request to fully and completely assign such Work and copyright therein to Employer, its successors or nominees, and that Executive hereby appoints Employer as attorney-in-fact to execute and deliver any such documents on Executive’s behalf in the event Executive should fail or refuse to do so within a reasonable period following Employer’s request.

12. Inventions and Patents. For purposes of this Agreement, “Inventions” includes, without limitation, information, inventions, contributions, improvements, ideas, or discoveries, whether protectable or not, and whether or not conceived or made during work hours. Executive agrees that all Inventions conceived or made by Executive during the period of employment with Employer belong to Employer, provided they grow out of Executive’s work with Employer or are related in some manner to the Business, including, without limitation, research and product development, and projected business of Employer or its affiliated companies. Accordingly, Executive will:

a. Make adequate written records of such Inventions, which records will be Employer’s property;

b. Assign to Employer, at its request, any rights Executive may have to such Inventions for the U.S. and all foreign countries;

c. Waive and agree not to assert any moral rights Executive may have or acquire in any Inventions and agree to provide written waivers from time to time as requested by Employer; and

d. Assist Employer (at Employer’s expense) in obtaining and maintaining patents or copyright registrations with respect to such Inventions.

Executive understands and agrees that Employer or its designee will determine, in its sole and absolute discretion, whether an application for patent will be filed on any Invention that is the exclusive property of Employer, as set forth above, and whether such an application will be abandoned prior to issuance of a patent. Employer will pay to Executive, either during or after the term of this Agreement, the following amounts if Executive is sole inventor, or Executive’s proportionate share if Executive is joint inventor: $750 upon filing of the initial application for patent on such Invention; and $1,500 upon issuance of a patent resulting from such initial patent application, provided Executive is named as an inventor in the patent.

Executive further agrees that Executive will promptly disclose in writing to Employer during the term of Executive’s employment and for one (1) year thereafter, all Inventions whether developed during the time of such employment or thereafter (whether or not Employer has rights in such Inventions) so that Executive’s rights and Employer’s rights in such Inventions can be determined. Except as set forth on the initialed Exhibit B (List of Inventions) to this Agreement, if any, Executive represents and warrants that Executive has no Inventions, software, writings or other works of authorship useful to Employer in the normal course of the Business, which were conceived, made or written prior to the date of this Agreement and which are excluded from the operation of this Agreement.

NOTICE: In accordance with Washington law, this Section 12 does not apply to Inventions for which no equipment, supplies, facility, or trade secret information of Employer was used and which was developed entirely on Executive’s own time, unless: (a) the Invention relates (i) directly to the business of Employer or (ii) to Employer’s actual or demonstrably anticipated research or development, or (b) the Invention results from any work performed by Executive for Employer.

13. Remedies. Notwithstanding other provisions of this Agreement regarding dispute resolution, Executive agrees that Executive’s violation of any of Sections 9, 10, 11 or 12 of this Agreement would cause Employer irreparable harm which would not be adequately compensated by monetary damages and that an injunction may be granted by any court or courts having jurisdiction, restraining Executive from violation of the terms of this Agreement, upon any breach or threatened breach of Executive of the obligations set forth in any of Sections 9, 10, 11 or 12. The preceding sentence shall not be construed to limit Employer from any other relief or damages to which it may be entitled as a result of Executive’s breach of any provision of this Agreement, including Sections 9, 10, 11 or 12. Executive also agrees that a violation of any of Sections 9, 10, 11 or 12 would entitle Employer, in addition to all other remedies available at law or equity, to recover from Executive any and all funds, including, without limitation, wages, salary and profits, which will be held by Executive in constructive trust for Employer, received by Executive in connection with such violation.

14. Dispute Resolution. Except for the right of Employer and Executive to seek injunctive relief in court, any controversy, claim or dispute of any type arising out of or relating to Executive’s employment or the provisions of this Agreement shall be resolved in accordance with this Section 14 regarding resolution of disputes, which will be the sole and exclusive procedure for the resolution of any disputes. This Agreement shall be enforced in accordance with the Federal Arbitration Act, the enforcement provisions of which are incorporated by this reference. Matters subject to these provisions include, without limitation, claims or disputes based on statute, contract, common law and tort and will include, for example, matters pertaining to termination, discrimination, harassment, compensation and benefits. Matters to be resolved under these procedures also include claims and disputes arising out of statutes such as the Fair Labor Standards Act, Title VII of the Civil Rights Act, the Age Discrimination in Employment Act, the Washington Minimum Wage Act, and the Washington Law Against Discrimination. Nothing in this provision is intended to restrict Executive from submitting any matter to an administrative agency with jurisdiction over such matter.

a. Mediation. Employer and Executive will make a good faith attempt to resolve any and all claims and disputes by submitting them to mediation in Snohomish County, Washington before resorting to arbitration or any other dispute resolution procedure. The mediation of any claim or dispute must be conducted in accordance with the then-current JAMS procedures for the resolution of employment disputes by mediation, by a mediator who has had both training and experience as a mediator of general employment and commercial matters. If the parties to this Agreement cannot agree on a mediator, then the mediator will be selected by JAMS in accordance with JAMS’ strike list method. Within thirty (30) days after the selection of the mediator, Employer and Executive and their respective attorneys will meet with the mediator for one mediation session of at least four hours. If the claim or dispute cannot be settled during such mediation session or mutually agreed continuation of the session, either Employer or Executive may give the mediator and the other party to the claim or dispute written notice declaring the end of the mediation process. All discussions connected with this mediation provision will be confidential and treated as compromise and settlement discussions. Nothing disclosed in such discussions, which is not independently discoverable, may be used for any purpose in any later proceeding. The mediator’s fees will be paid in equal portions by Employer and Executive, unless Employer agrees to pay all such fees.

b. Arbitration. If any claim or dispute has not been resolved in accordance with Section a, then the claim or dispute will be determined by arbitration in accordance with the then-current JAMS employment arbitration rules and procedures, except as modified herein. The arbitration will be conducted by a sole neutral arbitrator who has had both training and experience as an arbitrator of general employment and commercial matters and who is and for at least ten (10) years has been, a partner, a shareholder, or a member in a law firm. The arbitration shall be held in Snohomish County, Washington. If Employer and Executive cannot agree on an arbitrator, then the arbitrator will be selected by JAMS in accordance with Rule 15 of the JAMS employment arbitration rules and procedures. No person who has served as a mediator under the mediation provision, however, may be selected as the arbitrator for the same claim or dispute. Reasonable discovery will be permitted and the arbitrator may decide any issue as to discovery. The arbitrator may decide any issue as to whether or as to the extent to which any dispute is subject to the dispute resolution provisions in Section 14 and the arbitrator may award any relief permitted by law. The arbitrator must base the arbitration award on the provisions of Section 14 and applicable law and must render the award in writing, including an explanation of the reasons for the award. Judgment upon the award may be entered by any court having jurisdiction of the matter, and the decision of the arbitrator will be final and binding. The statute of limitations applicable to the commencement of a lawsuit will apply to the commencement of an arbitration under Section b. The arbitrator’s fees will be paid in equal portions by Employer and Executive, unless Employer agrees to pay all such fees.

15. Fees Related to Dispute Resolution. Unless otherwise agreed, the prevailing party will be entitled to its costs and attorneys’ fees incurred in any litigation or dispute relating to the interpretation or enforcement of this Agreement.

16. 409A. It is intended that any payment or benefit that is provided pursuant to or in connection with this Agreement that is considered to be deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended (“Code”) shall be paid and provided in a manner, and at such time and form, as complies with the applicable requirements of Section 409A of the Code to avoid the unfavorable tax consequences provided therein for non-compliance. It is further intended that the payments hereunder shall, to the maximum extent permissible under Section 409A of the Code, be exempt from Section 409A of the Code under either (i) the exception for involuntary separation pay to the extent that all payments are payable within the limitations described in Treasury Regulation Section 1.409A-1(b)(9), or (ii) the short-term deferral exception described in Treasury Regulation Section 1.409A-1(b)(4) to the extent that all payments are payable no later than two and a half months after the end of the first taxable year in which the right to the payment is no longer subject to a substantial risk of forfeiture.

a. If the Executive is a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code at such time, any payments to be made or benefits to be delivered in connection with the Executive’s “Separation from Service” (as defined below) that constitute deferred compensation subject to Section 409A of the Code shall not be made until the later of (i) eighteen months following the Effective Date or (ii) six months plus one day after the Executive’s Separation from Service (the “409A Deferral Period”) as required by Section 409A of the Code, provided that the payment of any such deferred compensation may be paid immediately following the Executive’s death. Payments of any such deferred compensation otherwise due to be made in installments or periodically during the 409A Deferral Period shall be accumulated and paid in a lump sum as soon as the 409A Deferral Period ends, and the balance of the payment shall be made as otherwise scheduled.

b. For purposes of this Agreement, all rights to payments and benefits hereunder shall be treated as rights to receive a series of separate payments and benefits to the fullest extent allowed by Section 409A of the Code.

c. For purposes of this Agreement, with respect to the timing of any amounts that constitute deferred compensation subject to Section 409A of the Code that depends on termination of employment or separation from service, termination of employment or separation from service shall mean a “separation from service” within the meaning of Section 409A of the Code where it is reasonably anticipated that no further services would be performed after such date or that the level of bona fide services the Executive would perform after that date (whether as an employee or independent contractor) would permanently decrease to a level less than or equal to twenty percent (20%) of the average level of bona fide services the Executive performed over the immediately preceding thirty-six (36) month period.

17. Disclosure. Executive agrees fully and completely to reveal the terms of this Agreement to any future employer or potential employer of Executive and authorizes Employer, at its election, to make such disclosure.

18. Representation of Executive. Executive represents and warrants to Employer that Executive is free to enter into this Agreement and has no contract, commitment, arrangement or understanding to or with any party that restrains or is in conflict with Executive’s performance of the covenants, services and duties provided for in this Agreement, and is not contravene the terms of any statute, law, or regulation to which Executive is subject. Executive agrees to indemnify Employer and to hold it harmless against any and all liabilities or claims arising out of any unauthorized act or acts by Executive that, the foregoing representation and warranty to the contrary notwithstanding, are in violation, or constitute a breach, of any such contract, commitment, arrangement or understanding.

19. Conditions of Employment. Employer’s obligations to Executive under this Agreement are conditioned upon Executive’s timely compliance with requirements of the United States immigration laws.

20. Assignability. This Agreement shall not be assignable by Executive. This Agreement may be assigned by the Company to a company which is a successor in interest to substantially all of the business operations of the Company. Such assignment shall become effective when the Company notifies the Executive of such assignment or at such later date as may be specified in such notice. Upon such assignment, the rights and obligations of the Company hereunder shall become the rights and obligations of such successor company, provided that any assignee expressly assumes the obligations, rights and privileges of this Agreement.

21. Notices. Any notices required or permitted to be given hereunder are sufficient if in writing and delivered by hand, by facsimile, by registered or certified mail, postage prepaid, or by overnight courier, to Executive at Executive’s home address as most recently updated in Executive’s Human Resources records, or to BioLife Solutions, Inc., 3303 Monte Villa Parkway, #310, Bothell, WA 98021, Attention: Chief Executive Officer. Notices shall be deemed to have been given (i) upon delivery, if delivered by hand or by email, (ii) seven days after mailing, if mailed, (iii) one business day after delivery, if delivered by courier, and (iv) one business day following receipt of an appropriate electronic confirmation, if by facsimile.

22. Severability. If any provision of this Agreement or compliance by any of the parties with any provision of this Agreement constitutes a violation of any law, or is or becomes unenforceable or void, then such provision, to the extent only that it is in violation of law, unenforceable or void, shall be deemed modified to the extent necessary so that it is no longer in violation of law, unenforceable or void, and such provision will be enforced to the fullest extent permitted by law. The Parties shall engage in good faith negotiations to modify and replace any provision which is declared invalid or unenforceable with a valid and enforceable provision, the economic effect of which comes as close as possible to that of the invalid or unenforceable provision which it replaces. If such modification is not possible, said provision, to the extent that it is in violation of law, unenforceable or void, shall be deemed severable from the remaining provisions of this Agreement, which provisions will remain binding on the parties.

23. Waivers. No failure on the part of either party to exercise, and no delay in exercising, any right or remedy hereunder will operate as a waiver thereof; nor will any single or partial waiver of a breach of any provision of this Agreement operate or be construed as a waiver of any subsequent breach; nor will any single or partial exercise of any right or remedy hereunder preclude any other or further exercise thereof or the exercise of any other right or remedy granted hereby or by law.

24. Governing Law. Except as provided in Section 14 above, the validity, construction and performance of this Agreement shall be governed by the laws of the State of Washington without regard to the conflicts of law provisions of such laws. The parties hereto expressly recognize and agree that the implementation of this Section 24 is essential in light of the fact that Employer has its corporate headquarters and its principal executive offices within the State of Washington, and there is a critical need for uniformity in the interpretation and enforcement of the employment agreements between Employer and its key employees. The Snohomish County Superior Court in Washington shall have exclusive jurisdiction of any lawsuit arising from or relating to Executive’s employment with, or termination from, Employer, or arising from or relating to this Agreement. Executive consents to such venue and personal jurisdiction.

25. Counterparts. This agreement may be executed in counterpart in different places, at different times and on different dates, and in that case all executed counterparts taken together collectively constitute a single binding agreement.

26. Costs and Fees Related to Negotiation and Execution of Agreement. Each Party Shall be responsible for the payment of its own costs and expenses, including legal fees and expenses, in connection with the negotiation and execution of this Agreement. Neither Party will be liable for the payment of any commissions or compensation in the nature of finders' fees or brokers' fees, gratuity or other similar thing or amount in consideration of the other Party entering into this Agreement to any broker, agent or third party acting on behalf of the other Party.

27. Entire Agreement. This instrument contains the entire agreement of the parties with respect to the relationship between Executive and Employer and supersedes all prior agreements and understandings, and there are no other representations or agreements other than as stated in this Agreement related to the terms and conditions of Executive’s employment. This Agreement may be changed only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension or discharge is sought, and any such modification will be signed by an authorized representative of Employer.

IN WITNESS WHEREOF, the parties have duly signed and delivered this Agreement as of the day and year first above written.

EMPLOYER

By	/s/ Michael Rice

Title: Chief Executive Officer

~~EXECUTIVE~~

/s/ Karen Foster
Karen Foster

EXHIBIT A

DISCLOSURE OF OUTSIDE BOARD OF DIRECTORS AND TRUSTEE POSITIONS

None

EXHIBIT B

LIST OF INVENTIONS

None

EX-10.3 4 v439570_ex10-3.htm EXHIBIT 10.3

Exhibit 10.3

EXECUTIVE EMPLOYMENT AGREEMENT

THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”), effective May 3, 2016 (“Effective Date”), is made between BioLife Solutions Inc., a Delaware corporation (“Employer” or the “Company”), and Roderick de Greef (“Executive”). Executive and the Company are sometimes referred to herein as the “Parties.”

RECITALS

A. Employer is in the business (the “Business”) of manufacturing and marketing proprietary biopreservation media for cells, tissues, and organs.

C. Executive desires to be assured of the salary and other benefits provided for in this Agreement.

AGREEMENT

1. Employment.

a. Employer hereby employs Executive, and Executive agrees to be employed as Chief Financial Officer (“CFO”), in accordance with the terms and conditions set forth in this Agreement. Changes may be made from time to time by Employer / the Board in its sole discretion to the duties, authorities, reporting relationships and title of Executive.

b. Executive will devote full time, attention, and best efforts to achieving the purposes and discharging the responsibilities of the CFO. Executive will comply with all rules, policies and procedures of Employer as modified from time to time, including without limitation, rules and procedures set forth in the Employer’s employee handbook, supervisor’s manuals and operating manuals. Executive will perform all of Executive’s responsibilities in compliance with all applicable laws and will ensure that the operations that Executive manages are in compliance with all applicable laws. During Executive’s employment, Executive will not engage in any other business activity which, in the reasonable judgment of the Employer, conflicts with the duties of Executive under this Agreement, whether or not such activity is pursued for gain, profit or other pecuniary advantage.

c. Nothing herein shall preclude Executive from: (1) continuing to serve as an officer or on the board of directors or trustees of any business corporation or any charitable organization on which he currently serves and which is identified on Exhibit A hereto, or (2) subject to the prior approval of the Board, appointment to any additional directorships or trusteeships, or (3) serving in an advisory role for other business entities, provided in each case, and in the aggregate, that such activities do not interfere with the performance of Executive’s duties hereunder or conflict with Section 8 of this Agreement.

3. Compensation. For the duration of Executive’s employment hereunder, the Executive will be entitled to compensation which will be computed and paid pursuant to the following subparagraphs.

a. Base Salary. Employer will pay to Executive a base salary (“Base Salary”) at an annual rate of three hundred thousand Dollars ($300,000), payable in such installments (but in no event less than monthly), subject to withholdings and deductions as required or permitted by law, as is Employer’s policy with respect to other employees. Executive’s Base Salary will be reviewed periodically by the Board of Directors of Employer during the term of Executive’s employment and may be adjusted in the sole discretion of the Board of Directors based on such review, but will not be reduced by Employer unless a material adverse change in the financial condition or operations of Employer has occurred or unless Executive’s responsibilities are altered to reflect less responsibility.

4. Other Benefits.

b. Vacations, Holidays and Expenses. Executive will be provided accrued paid vacation of four (4) weeks each calendar year, which shall be the maximum number of days Executive may accrue at any time, and which shall be taken at such times as are consistent with Executive’s responsibilities hereunder. Executive will be provided such holidays and vacation as Executive makes available to its management level employees generally. Employer will reimburse Executive in accordance with company policies and procedures for reasonable expenses necessarily incurred in the performance of duties hereunder against appropriate receipts and vouchers indicating the specific business purpose for each such expenditure. In no case shall any reimbursement be made later than December 31 of the year following the calendar year in which such expense is incurred.

5. Termination Or Discharge By Employer.

(i) any breach of this Agreement by Executive, including, without limitation, breach of Executive’s covenants in Sections 9, 10, 11 and 12;

(ii) any failure to perform assigned job responsibilities that continues unremedied for a period of ten (10) days after written notice to Executive by Employer;

(iv) commission of a felony or misdemeanor or failure to contest prosecution for a felony or misdemeanor;

(vi) the Employer’s reasonable belief that Executive engaged in unethical practices, dishonesty or disloyalty;

(vii) or any reason that would constitute Cause under the laws the State of Washington.

Upon termination of Executive’s employment hereunder for Cause, the Company shall pay the Executive no later than fourteen (14) days from the termination date in a lump sum: (i) his salary through the date of termination, (ii) for any unused vacation time, and (iii) for any unreimbursed business expenses that are subject to reimbursement under Employer’s then current policy on business expenses. Executive will have no rights to any unvested benefits or any other compensation or payments after the termination date.

Upon termination of Executive’s employment hereunder due to death or disability, the Company shall pay the Executive no later than fourteen (14) days from the termination date in a lump sum: (i) his salary through the date of termination, (ii) for any unused vacation time, and (iii) for any unreimbursed business expenses that are subject to reimbursement under Employer’s then current policy on business expenses. Upon termination of Executive’s employment hereunder due to death or disability, Executive or Executive’s estate (as the case may be) shall be entitled to receive any vested benefits required to be paid by law and any vested compensation required to be paid by law. Executive and Executive’s estate will have no rights to any unvested benefits or any other compensation or payments after the termination date.

(i)

(i) his salary through the date of termination, (ii) for any unused vacation time, and (iii) for any unreimbursed business expenses that are subject to reimbursement under Employer’s then current policy on business expenses.

(ii)

severance pay of six (6) months’ worth of Executive’s salary at the rate in effect on the termination date.

Such payments will be subject to all appropriate deductions and withholdings. Upon termination, Executive will have no rights to any unvested benefits or any other compensation.

d. Change in Control.

(i) For purposes of this Agreement, Change in Control shall mean (i) the consummation of a merger or consolidation of the Company with or into another entity, (ii) the dissolution, liquidation or winding up of the Company or (iii) the sale of all or substantially all of the Company's assets. The foregoing notwithstanding, a merger or consolidation of the Company shall not constitute a "Change in Control" if immediately after such merger or consolidation a majority of the voting power of the capital stock of the continuing or surviving entity, or any direct or indirect parent corporation of such continuing or surviving entity, will be owned by the persons who were the Company's stockholders immediately prior to such merger or consolidation in substantially the same proportions as their ownership of the voting power of the Company's capital stock immediately prior to such merger or consolidation.

(ii) Employer may terminate Executive’s employment under this Agreement upon or within 90 days following a Change in Control without advance notice; provided, however, that Employer will pay, no later than sixty (60) days from the termination date in a lump sum:

(a)

(b)

as severance pay, twelve (12) months’ worth of Executive’s salary at the rate in effect on the termination date,

(c)

the amount equal to the cost of twelve (12) months’ medical insurance premiums at a monthly amount equal to the amount of COBRA coverage in effect as of the termination date; and

(d)

an additional tax gross-up payment in an amount necessary so that the amount received by Executive to cover COBRA premiums under Section 5(d)(ii)(c) after all applicable withholding tax is deducted (using applicable supplemental wage withholding rates) is the full amount Executive would have received under Section 5(d)(ii)(c) if no tax withholding was made.

Such payments will be subject to all appropriate deductions and withholdings. Upon termination, Executive will have no rights to any unvested benefits or any other compensation.

(iii) Executive shall only be entitled to such severance pay if, within thirty (30) days following the date of termination, both Employer and Executive have signed (and then Executive does not rescind, as may be permitted by law) a mutual general release of claims in a form mutually acceptable to both parties (provided, however, that such release of claims shall only require each party to release the other party from claims relating directly to Executive’s employment and the termination thereof, and shall not require Executive to release claims relating to vested employee benefits or relating to other matters, including, but not limited to, claims relating to his status as a shareholder of the Company.

6. No Fault Termination By Executive. Executive may terminate Executive’s employment under this Agreement for any reason provided that Executive gives Employer at least ninety (90) days’ notice in writing. Employer may, at its option, accelerate such termination date to any date at least two weeks after Executive’s notice of termination. Employer may also, at its option, relieve Executive of all duties and authority after notice of termination has been provided. All compensation, payments and unvested benefits will cease on the termination date. Employer will pay Executive (i) Executive’s salary through the date of termination, (ii) for any unused vacation time, and (iii) for any unreimbursed business expenses that are subject to reimbursement under Employer’s then current policy on business expenses.

a. Employer’s material breach of the terms of this Agreement or any other written agreement between Executive and Employer;

b. the assignment to Executive of any duties that are substantially inconsistent with or materially diminish Executive’s position prior to execution of this Agreement;

c. a material reduction of Executive’s salary, other than as a result of a general salary reduction affecting substantially all Company employees;

d. any failure by the Company to obtain the assumption of this Agreement by any successor or assign of the Company; or

e. a requirement that the Executive be based at any office or location more than 50 miles from Executive’s primary work location prior to the Effective Date of this Agreement.

Provided that Executive has provided with notice of the existence of a condition giving rise to “Good Reason” to terminate within ninety (90) days following the initial existence of such a condition, Employer shall have thirty (30) days to cure any such alleged breach, assignment, reduction or requirement under Subsections a, b, c and e, above, after Executive provides Employer written notice of the actions or omissions constituting such breach, assignment, reduction or requirement.

If Executive resigns his employment for Good Reason, Executive shall be paid no later than sixty (60) days from the termination date in a lump sum:

severance pay of six (6) months’ worth of Executive’s salary at the rate in effect on the termination date.

Such payments will be subject to all appropriate deductions and withholdings. Upon termination, Executive will have no rights to any unvested benefits or any other compensation.

c. Directly or indirectly solicit, divert, take away or attempt to solicit, divert or take away any customers of Employer or any of its affiliates; or

For the purposes of this Section 9, businesses that are deemed to compete with Employer include, without limitation, businesses engaged in manufacturing and marketing biopreservation media for cells, tissues, and organs or cold chain management products and/or services. The geographic scope of the prohibitions in this Section 9 shall be any city, town or county in which the Company conducts or does any business as of or within one (1) year of Executive’s last day of employment with the Company. Notwithstanding Executive’s obligations under this Section 9, Executive will be entitled to own, as a passive investor, up to five percent (5%) of any publicly traded company without violating this provision.

a. Make adequate written records of such Inventions, which records will be Employer’s property;

b. Assign to Employer, at its request, any rights Executive may have to such Inventions for the U.S. and all foreign countries;

c. Waive and agree not to assert any moral rights Executive may have or acquire in any Inventions and agree to provide written waivers from time to time as requested by Employer; and

d. Assist Employer (at Employer’s expense) in obtaining and maintaining patents or copyright registrations with respect to such Inventions.

IN WITNESS WHEREOF, the parties have duly signed and delivered this Agreement as of the day and year first above written.

EMPLOYER


By	/s/ Michael Rice

Title:	Chief Executive Officer


EXECUTIVE

/s/ Roderick de Greef
Roderick de Greef

EXHIBIT A

DISCLOSURE OF OUTSIDE BOARD OF DIRECTORS AND TRUSTEE POSITIONS

EXHIBIT B

LIST OF INVENTIONS

EX-10.4 5 v439570_ex10-4.htm EXHIBIT 10.4

Exhibit 10.4

BioLife Solutions, INC.
RESTRICTED STOCK PURCHASE AGREEMENT
UNDER THE
AMENDED AND RESTATED 2013 PERFORMANCE INCENTIVE PLAN

THIS RESTRICTED STOCK PURCHASE AGREEMENT (the “Agreement”) is entered into as of , 20 by and between (hereinafter referred to as “Purchaser”), and BioLife Solutions, Inc., a Delaware corporation (hereinafter referred to as the “Company”), pursuant to the Company’s Amended and Restated 2013 Performance Incentive Plan, as amended (the “Plan”). Any capitalized term not defined herein shall have the same meaning ascribed to it in the Plan.

RECITALS:

A. Purchaser is an employee, director, consultant or other Service Provider, and in connection therewith has rendered services for and on behalf of the Company.

B. The Company desires to issue shares of Common Stock to Purchaser for the consideration set forth herein to provide an incentive for Purchaser to remain a Service Provider of the Company and to exert added effort towards its growth and success.

NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth, and for other good and valuable consideration, the parties agree as follows:

1. Issuance of Shares. The Company hereby offers to issue to Purchaser an aggregate of ( ) shares of Common Stock of the Company (the “Shares”) on the terms and conditions herein set forth. Unless this offer is earlier revoked in writing by the Company, Purchaser shall have ten (10) days from the date of the delivery of this Agreement to Purchaser to accept the offer of the Company by executing and delivering to the Company two copies of this Agreement, without condition or reservation of any kind whatsoever, together with the consideration to be delivered by Purchaser pursuant to Section 2 below.

2. Consideration. The purchase price for the Shares shall be $ per share, or $ in the aggregate. Any purchase price more than zero shall be paid by the delivery of Purchaser’s check payable to the Company (or payment in such other form of lawful consideration as the Administrator may approve from time to time under the provisions of Section 6.3 of the Plan).

3. Vesting of Shares.

(a) Subject to Section 3(b) below, the Shares acquired hereunder shall vest and become “Vested Shares” as follows:

Upon the date set forth below:		Shares that become Vested Shares:
		Shares
		Shares
		Shares

Page 1 of 7

Shares which have not yet become vested are herein called “Unvested Shares.” No additional Shares shall vest after the date of termination of Purchaser’s Continuous Service.

As used herein, the term “Continuous Service” means (i) employment by either the Company or any parent or subsidiary corporation of the Company, or by any successor entity following a Change in Control, which is uninterrupted except for vacations, illness (except for permanent disability, as defined in Section 22(e)(3) of the Code), or leaves of absence which are approved in writing by the Company or any of such other employer corporations, if applicable, (ii) service as a member of the Board of Directors of the Company until Purchaser resigns, is removed from office, or Purchaser’s term of office expires and he or she is not reelected, or (iii) so long as Purchaser is engaged as a consultant or Service Provider to the Company or other corporation referred to in clause (i) above.

(b) Notwithstanding Section 3(a), if Purchaser holds Shares at the time a Change in Control occurs, all Repurchase Rights (as defined below) shall automatically terminate immediately prior to the consummation of such Change in Control, and the Shares subject to those terminated Repurchase Rights shall immediately vest in full. If the Repurchase Rights automatically terminate in accordance with the provisions of this subsection (b), then the Administrator shall cause written notice of the Change in Control transaction to be given to Purchaser not less than fifteen (15) days prior to the anticipated effective date of the proposed transaction.

4. Reconveyance Upon Termination of Service.

(a) Repurchase Right. The Company shall have the right (but not the obligation) to repurchase all or any part of the Unvested Shares (the “Repurchase Right”) in the event that the Purchaser’s Continuous Service terminates for any reason. Upon exercise of the Repurchase Right, the Purchaser shall be obligated to sell his or her Unvested Shares to the Company, as provided in this Section 4. If the Purchase Price is zero, then Purchaser shall be obligated to transfer his or her Unvested Shares to the Company without consideration.

(b) Consideration for Repurchase Right. The repurchase price of the Unvested Shares (the “Repurchase Price”) shall be equal to the Purchase Price, if any, of such Unvested Shares.

(c) Procedure for Exercise of Reconveyance Option. For sixty (60) days after the date of termination of Purchaser’s Continuous Service or other event described in this Section 4, the Company may exercise the Repurchase Right by giving Purchaser and/or any other person obligated to sell written notice of the number of Unvested Shares which the Company desires to purchase. The Repurchase Price for the Unvested Shares shall be payable, at the option of the Company, by check or by cancellation of all or a portion of any outstanding indebtedness of Purchaser to the Company, or by any combination thereof.

(d) Notification and Settlement. In the event that the Company has elected to exercise the Repurchase Right as to part or all of the Unvested Shares within the period described above, Purchaser or such other person shall deliver to the Company certificate(s) representing the Unvested Shares to be acquired by the Company within thirty (30) days following the date of the notice from the Company. The Company shall deliver to Purchaser against delivery of the Unvested Shares, checks of the Company payable to Purchaser and/or any other person obligated to transfer the Unvested Shares in the aggregate amount of the Repurchase Price, if any, to be paid as set forth in Section 4(b) above.

Page 2 of 7

(e) Deposit of Unvested Shares. Purchaser shall deposit with the Company certificates representing the Unvested Shares, together with a duly executed stock assignment separate from certificate in blank, which shall be held by the Secretary of the Company. Purchaser shall be entitled to vote and to receive dividends and distributions on all such deposited Unvested Shares.

(f) Termination. The provisions of this Section 4 shall automatically terminate in accordance with Section 3(b) above.

(g) Assignment. The Company may assign its Repurchase Right under this Section 4 without the consent of the Purchaser.

5. Restrictions on Unvested Shares. Unvested Shares may not be sold, transferred, pledged, or otherwise disposed of, except that such Unvested Shares may be transferred to a trust established for the sole benefit of the Purchaser and/or his or her spouse, children or grandchildren. Any Unvested Shares that are transferred as provided herein remain subject to the terms and conditions of this Agreement.

6. Adjustments Upon Changes in Capital Structure. In the event that the outstanding shares of Common Stock of the Company are hereafter increased or decreased or changed into or exchanged for a different number or kind of shares or other securities of the Company by reason of a recapitalization, stock split, combination of shares, reclassification, stock dividend, or other change in the capital structure of the Company, then Purchaser shall be entitled to new or additional or different shares of stock or securities, in order to preserve, as nearly as practical, but not to increase, the benefits of Purchaser under this Agreement, in accordance with the provisions of Section 4.2 of the Plan. Such new, additional or different shares shall be deemed “Shares” for purposes of this Agreement and subject to all of the terms and conditions hereof.

7. Shares Free and Clear. All Shares purchased by the Company pursuant to this Agreement shall be delivered by Purchaser free and clear of all claims, liens and encumbrances of every nature (except the provisions of this Agreement and any conditions concerning the Shares relating to compliance with applicable federal or state securities laws), and the purchaser thereof shall acquire full and complete title and right to all of such Shares, free and clear of any claims, liens and encumbrances of every nature (again, except for the provisions of this Agreement and such securities laws).

8. Limitation of Company’s Liability for Nonissuance; Unpermitted Transfers.

(a) The Company agrees to use its reasonable best efforts to obtain from any applicable regulatory agency such authority or approval as may be required in order to issue and sell the Shares to Purchaser pursuant to this Agreement. The inability of the Company to obtain, from any such regulatory agency, authority or approval deemed by the Company’s counsel to be necessary for the lawful issuance and sale of the Shares hereunder and under the Plan shall relieve the Company of any liability in respect of the nonissuance or sale of such Shares as to which such requisite authority or approval shall not have been obtained.

Page 3 of 7

(b) The Company shall not be required to: (i) transfer on its books any Shares of the Company which shall have been sold or transferred in violation of any of the provisions set forth in this Agreement, or (ii) treat as owner of such Shares or to accord the right to vote as such owner or to pay dividends to any transferee to whom such Shares shall have been so transferred.

9. Notices. Any notice, demand or request required or permitted to be given under this Agreement shall be in writing and shall be deemed given when delivered personally or three (3) days after being deposited in the United States mail, as certified or registered mail, with postage prepaid, (or by such other method as the Administrator may from time to time deem appropriate), and addressed, if to the Company, at its principal place of business, Attention: the Chief Financial Officer, and if to the Purchaser, at his or her most recent address as shown in the employment or stock records of the Company.

10. Binding Obligations. All covenants and agreements herein contained by or on behalf of any of the parties hereto shall bind and inure to the benefit of the parties hereto and their permitted successors and assigns.

11. Captions and Section Headings. Captions and section headings used herein are for convenience only, and are not part of this Agreement and shall not be used in construing it.

12. Interpretation. All Shares are issued pursuant to the terms of the Plan, and shall in all respects be interpreted in accordance therewith. The Administrator shall interpret and construe this Agreement and the Plan, and any action, decision, interpretation or determination made in good faith by the Administrator shall be final and binding on the Company and the Purchaser. As used in this Agreement, the term “Administrator” shall refer to the committee of the Board of Directors of the Company appointed to administer the Plan, and if no such committee has been appointed, the term Administrator shall mean the Board of Directors.

13. Entire Agreement. This Agreement and the Plan constitute the entire agreement between the parties with respect to the subject matter hereof and supersede all prior or contemporaneous written or oral agreements and understandings of the parties, either express or implied.

14. Assignment. Purchaser shall have no right, without the prior written consent of the Company, to (i) sell, assign, mortgage, pledge or otherwise transfer any interest or right created hereby, or (ii) delegate his or her duties or obligations under this Agreement. This Agreement is made solely for the benefit of the parties hereto, and no other person, partnership, association or corporation shall acquire or have any right under or by virtue of this Agreement.

Page 4 of 7

15. Severability. Should any provision or portion of this Agreement be held to be unenforceable or invalid for any reason, the remaining provisions and portions of this Agreement shall be unaffected by such holding.

16. Counterparts. This Agreement may be executed in one or more counterparts, all of which taken together shall constitute one agreement and any party hereto may execute this Agreement by signing any such counterpart. This Agreement shall be binding upon Purchaser and the Company at such time as the Agreement, in counterpart or otherwise, is executed by Purchaser and the Company.

17. “Market Stand-Off” Agreement. Purchaser agrees in connection with any registration of the Company’s securities that, upon the request of the Company or the underwriters managing any public offering of the Company’s securities, Purchaser will not sell or otherwise dispose of any Shares acquired by Purchaser without the prior written consent of the Company or such underwriters, as the case may be, for a period of time (not to exceed 180 days) from the effective date of such registration as the Company or the underwriters may specify.

18. Tax Elections. Purchaser understands that Purchaser (and not the Company) shall be responsible for the Purchaser’s own tax liability that may arise as a result of the acquisition of the Shares. Purchaser acknowledges that Purchaser has considered the advisability of all tax elections in connection with the purchase of the Shares, including the making of an election under Section 83(b) under the Internal Revenue Code of 1986, as amended (“Code”); Purchaser further acknowledges that the Company has no responsibility for the making of such Section 83(b) election. In the event Purchaser determines to make a Section 83(b) election, Purchaser agrees to timely provide a copy of the election to the Company as required under the Code.

19. Attorneys’ Fees. If any party shall bring an action in law or equity against another to enforce or interpret any of the terms, covenants and provisions of this Agreement, the prevailing party in such action shall be entitled to recover reasonable attorneys’ fees and costs.

Page 5 of 7

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

THE COMPANY:			PURCHASER:

BioLife Solutions, INC.

By:

Name:
			(Print Name)
Title:

	Address:

Page 6 of 7

CONSENT AND RATIFICATION OF SPOUSE

The undersigned, the spouse of , a party to the attached Restricted Stock Purchase Agreement (the “Agreement”), dated as of , hereby consents to the execution of said Agreement by such party; and ratifies, approves, confirms and adopts said Agreement, and agrees to be bound by each and every term and condition thereof as if the undersigned had been a signatory to said Agreement, with respect to the Shares (as defined in the Agreement) made the subject of said Agreement in which the undersigned has an interest, including any community property interest therein.

I also acknowledge that I have been advised to obtain independent counsel to represent my interests with respect to this Agreement but that I have declined to do so and I hereby expressly waive my right to such independent counsel.

Date:
			(Signature)


			(Print Name)

Page 7 of 7

EX-10.5 6 v439570_ex10-5.htm EXHIBIT 10.5

Exhibit 10.5

Option No.

BioLife Solutions, Inc.

STOCK OPTION AGREEMENT

Type of Option (check one): ¨ Incentive ¨ Nonqualified

This Stock Option Agreement (the “Agreement”) is entered into as of , 20 , by and between BioLife Solutions, Inc., a Delaware corporation (the “Company”), and (the “Optionee”) pursuant to the Company’s Amended & Restated 2013 Performance Incentive Plan, as amended (the “Plan”). Any capitalized term not defined herein shall have the same meaning ascribed to it in the Plan.

1. Grant of Option. The Company hereby grants to Optionee an option (the “Option”) to purchase all or any portion of a total of ( ) shares (the “Shares”) of the Common Stock of the Company at a purchase price of ($ ) per share (the “Exercise Price”), subject to the terms and conditions set forth herein and the provisions of the Plan. If the box marked “Incentive” above is checked, then this Option is intended to qualify as an “incentive stock option” as defined in Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”). If this Option fails in whole or in part to qualify as an incentive stock option, or if the box marked “Nonqualified” is checked, then this Option shall to that extent constitute a nonqualified stock option.

2. Vesting of Option. The right to exercise this Option shall vest in installments, and this Option shall be exercisable from time to time in whole or in part as to any vested installment, as follows:

Upon the date set forth below:		This Option shall be Exercisable as to:
		Shares
		Shares
		Shares

No additional Shares shall vest after the date of termination of Optionee’s “Continuous Service” (as defined below), but this Option shall continue to be exercisable in accordance with Section 3 hereof with respect to that number of Shares that have vested as of the date of termination of Optionee’s Continuous Service.

As used herein, the term “Continuous Service” means (i) employment by either the Company or any parent or subsidiary corporation of the Company, or by a corporation or a parent or subsidiary of a corporation issuing or assuming a stock option in a transaction to which Section 424(a) of the Code applies, which is uninterrupted except for vacations, illness (except for permanent disability, as defined in Section 22(e)(3) of the Code), or leaves of absence which are approved in writing by the Company or any of such other employer corporations, if applicable, (ii) service as a member of the Board of Directors of the Company until Optionee resigns, is removed from office, or Optionee’s term of office expires and he or she is not reelected, or (iii) so long as Optionee is engaged as a Service Provider to the Company or other corporation referred to in clause (i) above.

Page 1 of 6

3. Term of Option. The right of the Optionee to exercise this Option shall terminate upon the first to occur of the following:

(a) the expiration of ten (10) years from the date of this Agreement;

(b) the expiration of three (3) months from the date of termination of Optionee’s Continuous Service if such termination occurs for any reason other than permanent disability or death; provided, however, that if Optionee dies during such three-month period the provisions of Section 3(d) below shall apply; and provided, further, that if Section 3(d) does not apply, and on the last trading day within such three-month period Optionee is subject to a blackout imposed by the Company pursuant to which Optionee is restricted from exercising this Option or reselling the Shares issuable upon such exercise, the right of Optionee to exercise this Option shall continue until the tenth (10^th) day following the expiration of such blackout with respect to Optionee;

(c) the expiration of one (1) year from the date of termination of Optionee’s Continuous Service if such termination is due to permanent disability of the Optionee (as defined in Section 22(e)(3) of the Code);

(d) the expiration of one (1) year from the date of termination of Optionee’s Continuous Service if such termination is due to Optionee’s death or if death occurs during the three-month period following termination of Optionee’s Continuous Service specified in Section 3(b) above; or

(e) upon the consummation of a “Change in Control” (as defined in Section 2.7 of the Plan).

4. Exercise of Option. On or after the vesting of any portion of this Option in accordance with Sections 2 or 8 hereof, and until termination of the right to exercise this Option in accordance with Section 3 above, the portion of this Option which has vested may be exercised in whole or in part by the Optionee (or, after his or her death, by the person designated in Section 5 below) upon delivery of the following to the Company at its principal executive offices:

(a) a written notice of exercise which identifies this Agreement and states the number of Shares then being purchased (but no fractional Shares may be purchased);

(b) a check or cash in the amount of the Exercise Price (or payment of the Exercise Price in such other form of lawful consideration as the Administrator may approve from time to time under the provisions of Section 5.3 of the Plan);

(c) a check or cash in the amount reasonably requested by the Company to satisfy the Company’s withholding obligations under federal, state or other applicable tax laws with respect to the taxable income, if any, recognized by the Optionee in connection with the exercise of this Option (unless the Company and Optionee shall have made other arrangements for deductions or withholding from Optionee’s wages, bonus or other compensation payable to Optionee, or by the withholding of Shares issuable upon exercise of this Option or the delivery of Shares owned by the Optionee in accordance with Section 11.1 of the Plan, provided such arrangements satisfy the requirements of applicable tax laws); and

Page 2 of 6

(d) a letter, if requested by the Company, in such form and substance as the Company may require, setting forth the investment intent of the Optionee, or person designated in Section 5 below, as the case may be.

5. Death of Optionee; No Assignment. The rights of the Optionee under this Agreement may not be assigned or transferred except by will or by the laws of descent and distribution, and may be exercised during the lifetime of the Optionee only by such Optionee. Any attempt to sell, pledge, assign, hypothecate, transfer or dispose of this Option in contravention of this Agreement or the Plan shall be void and shall have no effect. If the Optionee’s Continuous Service terminates as a result of his or her death, and provided Optionee’s rights hereunder shall have vested pursuant to Section 2 hereof, Optionee’s legal representative, his or her legatee, or the person who acquired the right to exercise this Option by reason of the death of the Optionee (individually, a “Successor”) shall succeed to the Optionee’s rights and obligations under this Agreement. After the death of the Optionee, only a Successor may exercise this Option.

6. Representation of Optionee. Optionee acknowledges receipt of a copy of the Plan and understands that all rights and obligations connected with this Option are set forth in this Agreement and the Plan.

7. Adjustments Upon Changes in Capital Structure. In the event that the outstanding shares of Common Stock of the Company are hereafter increased or decreased or changed into or exchanged for a different number or kind of shares or other securities of the Company by reason of a recapitalization, stock split, reverse stock split, reclassification, stock dividend or other similar change in the capital structure of the Company, then appropriate adjustment shall be made by the Administrator to the number of Shares subject to the unexercised portion of this Option and to the Exercise Price per Share, in order to preserve, as nearly as practical, but not to increase, the benefits of the Optionee under this Option, in accordance with the provisions of Section 4.2 of the Plan.

8. Change in Control. In the event of a Change in Control (as defined in Section 2.7 of the Plan), the right to exercise this Option shall accelerate automatically and vest in full (notwithstanding the provisions of Section 2 above) effective as of immediately prior to the consummation of the Change in Control. If vesting of this Option will accelerate pursuant to the preceding sentence, the Administrator in its discretion may provide, in connection with the Change in Control transaction, for the purchase or exchange of this Option for an amount of cash or other property having a value equal to the difference (or “spread”) between: (x) the value of the cash or other property that the Optionee would have received pursuant to the Change in Control transaction in exchange for the Shares issuable upon exercise of this Option had this Option been exercised immediately prior to the Change in Control, and (y) the aggregate Exercise Price for such Shares. If the vesting of this Option will accelerate pursuant to this Section 8, then the Administrator shall cause written notice of the Change in Control transaction to be given to the Optionee not less than fifteen (15) days prior to the anticipated effective date of the proposed transaction.

Page 3 of 6

9. Rights as Stockholder. The Optionee (or transferee of this Option by will or by the laws of descent and distribution) shall have no rights as a stockholder with respect to any Shares covered by this Option until such person has duly exercised this Option, paid the Exercise Price and become a holder of record of the Shares purchased.

10. “Market Stand-Off” Agreement. Optionee agrees that, if requested by the Company or the managing underwriter of any proposed public offering of the Company’s securities, Optionee will not sell or otherwise transfer or dispose of any Shares held by Optionee without the prior written consent of the Company or such underwriter, as the case may be, during such period of time, not to exceed 180 days following the effective date of the registration statement filed by the Company with respect to such offering, as the Company or the underwriter may specify.

11. Interpretation. This Option is granted pursuant to the terms of the Plan, and shall in all respects be interpreted in accordance therewith. The Administrator shall interpret and construe this Option and the Plan, and any action, decision, interpretation or determination made in good faith by the Administrator shall be final and binding on the Company and the Optionee. As used in this Agreement, the term “Administrator” shall refer to the committee of the Board of Directors of the Company appointed to administer the Plan, and if no such committee has been appointed, the term Administrator shall mean the Board of Directors.

12. Limitation of Liability for Nonissuance. During the term of the Plan, the Company agrees at all times to reserve and keep available, and to use its reasonable best efforts to obtain from any regulatory body having jurisdiction any requisite authority in order to issue and sell, such number of shares of its Common Stock as shall be sufficient to satisfy its obligations hereunder and the requirements of the Plan. Inability of the Company to obtain, from any regulatory body having jurisdiction, authority deemed by the Company’s counsel to be necessary for the lawful issuance and sale of any shares of its Common Stock hereunder and under the Plan shall relieve the Company of any liability in respect of the nonissuance or sale of such shares as to which such requisite authority shall not have been obtained.

13. Notices. Any notice, demand or request required or permitted to be given under this Agreement shall be in writing and shall be deemed given when delivered personally or three (3) days after being deposited in the United States mail, as certified or registered mail, with postage prepaid, (or by such other method as the Administrator may from time to time deem appropriate), and addressed, if to the Company, at its principal place of business, Attention: the Chief Financial Officer, and if to the Optionee, at his or her most recent address as shown in the employment or stock records of the Company.

14. Severability. Should any provision or portion of this Agreement be held to be unenforceable or invalid for any reason, the remaining provisions and portions of this Agreement shall be unaffected by such holding.

Page 4 of 6

15. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall be deemed one instrument.

16. Tax Consequences and Reporting Obligation Upon Sale of Shares. If this Option is an “incentive stock option,” the tax benefits afforded to incentive stock options will be obtained by the Optionee only if the Shares received upon exercise of this Option are held for at least one year after the date of exercise of this Option and two years after the date this Option was granted to the Optionee. If the Optionee sells or otherwise transfers the Shares before the expiration of either of these one- or two-year periods, the sale or transfer will be treated for tax purposes as a “disqualifying disposition,” resulting in the following tax consequences: (a) the Optionee will not obtain the tax benefits afforded to incentive stock options, (b) the “spread” as of the date of exercise will be taxed to the Optionee at ordinary income tax rates, and (c) the amount of ordinary income resulting from the disqualifying disposition will be included in the Optionee’s W-2. These tax consequences are described in more detail in the prospectus that relates to the Plan, a copy of which was delivered to the Optionee with this Option. To assure that the Company has the information necessary to comply with its tax reporting obligations, Optionee agrees to promptly notify the Company if any Shares are sold or transferred less than one year after the date of exercise or less than two years after the date this Option was granted, and report information regarding the disqualifying disposition in accordance with procedures established by the Company for this purpose.

Page 5 of 6

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

BioLife Solutions, Inc.			OPTIONEE
a Delaware corporation

By:
			(Signature)

Name:
			(Type or print name)

Its:			Address:

Page 6 of 6

EX-10.6 7 v439570_ex10-6.htm EXHIBIT 10.6

Exhibit 10.6

[Letterhead of WAVI Holding AG]

May 12, 2016

VIA EMAIL AND AIR MAIL

BioLife Solutions, Inc.

Attention: Roderick de Greef

3303 Monte Villa Parkway, Suite 310

Bothell, Washington 98021

Re:

Commitment to provide US$4,000,000 credit financing.

Dear Rod:

WAVI Holding AG, a corporation organized under the laws of Switzerland (the “Lender”), agrees to lend to BioLife Solutions, Inc., a Delaware corporation (the “Borrower”), the sum of US$4,000,000 in a series of advances, as follows:

Amount to be Advanced (US$)		Date of Advance
US$	1,000,000	June 1, 2016
US$	1,000,000	September 1, 2016
US$	1,000,000	December 1, 2016
US$	1,000,000	March 1, 2017

The obligations of the Borrower with respect to the advances described in the preceding paragraph shall be evidenced by a promissory note of the Borrower (the “Note”) substantially in the form of Exhibit A attached to this letter.

In partial consideration for the Lender entering into this letter and agreeing to make the advances, the Borrower will issue to the Lender, as of the date hereof, a five year warrant (the “Warrant”) to purchase up to 550,000 shares of common stock of the Borrower (“Shares”, and together with the Note and the Warrants, the “Securities”) with an exercise price of $1.75 per Share, substantially in the form of Exhibit B attached to this letter.

Lender represents, warrants and covenants to and with the Borrower as follows:

(a) No Registration. The Lender understands that the Securities, and any securities underlying the Securities, will be “restricted securities” and have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”) or any applicable state securities law and may not be offered or sold in the United States or to U.S. Persons unless the securities are registered under the Securities Act or an exemption from the registration requirements of the Securities Act are available. “United States” and “U.S. Person” are as defined in Regulation S under the Securities Act.

[Signature Page to BioLife Commitment Letter]

(b) Own Account. The Lender is acquiring the Securities as principal for its own account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting the Lender’s right to sell Securities pursuant to any registration statement or otherwise in compliance with applicable federal and state securities laws) in violation of the Securities Act or any applicable state securities law. The Lender is acquiring the Securities hereunder in the ordinary course of its business.

(c) Accredited Investor. The Lender is, and on the date of each advance will be an “accredited investor”, as defined in Rule 501(a) of Regulation D under the Securities Act.

(d) Non-U.S. Lender. At the time the Lender was offered the Securities and at the time of the execution and delivery of this Agreement, it was not, and as of the date hereof it is not, and on the date of each advance it will not be, a U.S. Person or in the United States, nor will it be acquiring the Securities for the account or benefit of a U.S. Person or a person in the United States.

(e) Restrictions of Resale. The Lender agrees to offer, sell or otherwise transfer the Securities, and any underlying securities, only in accordance with the provisions of Regulation S under the Securities Act, pursuant to registration under the Securities Act, or pursuant to an available exemption from registration under the Securities Act. In addition, the Lender agrees not to engage in hedging transactions with regard to such securities unless in compliance with the Securities Act.

(f) Legend. The Lender understands and acknowledges that upon the original issuance of Securities, and until no longer required under the U.S. Securities Act or applicable state securities laws, the certificates representing the Securities and any securities underlying the Securities will bear a legend in substantially the following form:

THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”). SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) IF THE SECURITIES HAVE BEEN REGISTERED IN COMPLIANCE WITH THE REGISTRATION REQUIREMENTS UNDER THE U.S. SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, (C) IN COMPLIANCE WITH THE EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE U.S. SECURITIES ACT IN ACCORDANCE WITH RULE 144 THEREUNDER, IF APPLICABLE, AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, OR (D) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE STATE LAWS AND REGULATIONS GOVERNING THE OFFER AND SALE OF SECURITIES, AND THE HOLDER HAS, PRIOR TO SUCH SALE, FURNISHED TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING, OR OTHER EVIDENCE OF EXEMPTION, REASONABLY SATISFACTORY TO THE COMPANY. HEDGING TRANSACTIONS INVOLVING SUCH SECURITIES REPRESENTED HEREBY MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE U.S. SECURITIES ACT.

(g) Restrictions on Conversion Warrant Exercises. The Lender understands the restrictions on exercise set forth in the Warrant.

(h) Experience of the Lender. The Lender, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the acquisition of the Securities, and has so evaluated the merits and risks of such investment. The Lender is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

The Borrower will not register any transfer of Securities unless made in accordance with paragraph (e) above.

If the Borrower is in agreement with the terms of this letter, please countersign this letter in the space for the Borrower provided below and return a copy via email to the Lender and deliver the executed original to the Lender at its address provided above.

	Very truly yours,

	WAVI HOLDING AG

	By:	/s/ Walter Villiger
	Name: Walter Villiger
	Title: Chairman

Acknowledged and agreed to this

12th day of May, 2016.

BIOLIFE SOLUTIONS, INC.

By:	/s/ Roderick de Greef
Name:
Title:

EXHIBIT A

FORM OF PROMISSORY NOTE

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”). SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) IF THE SECURITIES HAVE BEEN REGISTERED IN COMPLIANCE WITH THE REGISTRATION REQUIREMENTS UNDER THE U.S. SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, (C) IN COMPLIANCE WITH THE EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE U.S. SECURITIES ACT IN ACCORDANCE WITH RULE 144 THEREUNDER, IF APPLICABLE, AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, OR (D) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE STATE LAWS AND REGULATIONS GOVERNING THE OFFER AND SALE OF SECURITIES, AND THE HOLDER HAS, PRIOR TO SUCH SALE, FURNISHED TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING, OR OTHER EVIDENCE OF EXEMPTION, REASONABLY SATISFACTORY TO THE COMPANY. HEDGING TRANSACTIONS INVOLVING SUCH SECURITIES REPRESENTED HEREBY MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE U.S. SECURITIES ACT.

PROMISSORY NOTE

US$4,000,000

May 12, 2016

FOR VALUE RECEIVED, the undersigned, BioLife Solutions, Inc., a Delaware corporation (“Borrower”) promises to pay to the order of WAVI Holding AG, a corporation organized under the laws of Switzerland (the “Lender”) at its office at Paradiesstrasse 25, CH-6845, Jona, Switzerland, in lawful money of the United States, or at such other address as the holder hereof may from time to time designate in writing, the principal amount of all loans made by the Lender to the Borrower under the terms of this Note (each an “Advance” and collectively the “Advances”). The aggregate principal amount of all Advances outstanding hereunder shall not exceed FOUR MILLION AND 00/100 UNITED STATES DOLLARS (US$4,000,000), and no Advance shall be made after June 1, 2017 (the “Maturity Date”).

This Note matures on the Maturity Date, and the outstanding principal amount of this Note shall be repaid in full on the Maturity Date.

This Note is unsecured.

Interest on the unpaid principal balance of this Note shall accrue from the date hereof at a per annum rate equal to ten percent (10%) calculated on the basis of a year consisting of twelve months of thirty days each. No provision of this Note shall require the payment or permit the collection of interest in excess of the rate permitted by applicable law.

Accrued interest at the rates referred to above shall be payable on the Maturity Date, when all unpaid accrued interest shall be due and payable in full.

Principal, interest and fees owed under this Note are payable in lawful money of the United States of America in immediately available funds.

All payments under this Note shall be applied initially against accrued interest and thereafter in reduction of principal. The principal amount hereof, together with accrued, unpaid interest hereon, may be prepaid at any time and from time to time without premium or penalty.

Any officer of the Borrower who has been disclosed to the Lender in writing as an authorized officer for such purposes (an “Authorized Person”) may request an Advance on any day other than a Saturday, Sunday or other day when commercial banks located in the State of Washington are not open for commercial banking business (each such day, a “Business Day”). Such request shall be made in writing delivered to the Lender by not later than 9:00 a.m. on the day two Business Days prior to the requested Advance.

The Borrower hereby authorizes the Lender to rely upon the written instructions of any person identifying himself or herself as an Authorized Person and upon any signature which the Lender believes to be genuine, and the Borrower shall be bound thereby in the same manner as if such person were authorized or such signature were genuine.

It is expressly understood that the Lender is under no obligation to make any Advance to the Borrower under this Note (whether by reason of any provision hereof or otherwise) (i) if an Event of Default, as hereinafter defined, has occurred and is continuing, or (ii) if such Advance or any part thereof would cause the aggregate amount of all Advances made hereunder to exceed $4,000,000.

The Borrower covenants and agrees that any and all payments under this shall be made without deduction or withholding for any taxes other than income or franchise taxes imposed on the Lender in any jurisdiction (“Subject Taxes”), except as required by applicable law. If any applicable law requires the deduction or withholding of any Subject Tax from any such payment, then the Borrower shall be entitled to make such deduction or withholding. If the Borrower is entitled to an exemption from or reduction of any Subject Tax with respect to payments made under this Note, the Lender agrees, by its acceptance of this Note, that it shall deliver to the Borrower, at the time or times reasonably requested by the Borrower, such properly completed and executed documentation reasonably requested by the Borrower as will permit such payments to be made without withholding or at a reduced rate of withholding and such other documentation prescribed by applicable law or reasonably requested by the Borrower as will enable the Borrower to determine whether or not the Lender is subject to backup withholding or information reporting requirements. Without limiting the generality of the foregoing, the Lender further agrees, by its acceptance of this Note, that it shall, to the extent it is legally entitled to do so, deliver to the Borrower on or prior to the date which is 10 days after the date of this Note (and from time to time thereafter upon the reasonable request of the Borrower), whichever of the following is applicable:

(1) if the Lender is claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under this Note, executed originals of IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding tax pursuant to the “interest” article of such tax treaty and (y) with respect to any other applicable payments under this Note, IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “business profits” or “other income” article of such Tax treaty;

(2) executed originals of IRS Form W-8ECI;

(3) if the Lender is claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Internal Revenue Code, (x) a certificate to the effect that the Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Internal Revenue Code, a “10 percent shareholder” of the Borrower within the meaning of Section 881(c)(3)(B) of the Internal Revenue Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Internal Revenue Code and (y) executed originals of IRS Form W-8BEN or IRS Form W-8BEN-E; or

(4) to the extent the Lender is not the beneficial owner, executed originals of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN, IRS Form W-8BEN-E, IRS Form W-8IMY or IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable.

The Lender further agrees, by its acceptance of this Note, that it shall, to the extent it is legally entitled to do so, deliver to the Borrower on or prior to the date which is 10 days after the date of this Note (and from time to time thereafter upon the reasonable request of the Borrower), executed originals of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit the Borrower to determine the withholding or deduction required to be made.

If a payment made to the Lender under this Note would be subject to U.S. federal withholding tax imposed by FATCA if the Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Internal Revenue Code, as applicable), the Lender further agrees, by its acceptance of this Note, that it shall deliver to the Borrower at the time or times prescribed by law and at such time or times reasonably requested by the Borrower such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Internal Revenue Code) and such additional documentation reasonably requested by the Borrower as may be necessary for the Borrower to comply with their obligations under FATCA and to determine that the Lender has complied with its obligations under FATCA or to determine the amount to deduct and withhold from such payment. For the purposes of this paragraph, “FATCA” means Sections 1471 through 1474 of the Internal Revenue Code, as the same may be amended after the date of this Note, and any current or future regulations or official interpretations thereof.

The Lender further agrees, by its acceptance of this Note, that it agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower in writing of its legal inability to do so.

If Lender determines, in its sole discretion exercised in good faith, that it has received a refund of any Subject Taxes as to which it has been indemnified pursuant to the preceding four paragraphs (including by the payment of additional amounts pursuant to such paragraphs), the Lender further agrees, by its acceptance of this Note, that it shall pay to the Borrower an amount equal to such refund (but only to the extent of indemnity payments made pursuant to such paragraphs), and without interest (other than any interest paid by the relevant governmental authority with respect to such refund).

The Borrower will not create, incur, assume or suffer to exist any Lien, or enter into, or make any commitment to enter into, any arrangement for the acquisition of any property through conditional sale, lease-purchase or other title retention agreements, with respect to any property now owned or hereafter acquired by the Borrower, other than a Permitted Lien. For purposes of this Note, the following terms have the definitions assigned to them:

“Lien” means, with respect to any person, any security interest, mortgage, pledge, lien, charge, encumbrance, title retention agreement or analogous instrument or device in, of or on any assets or properties of such person, now owned or hereafter acquired, whether arising by agreement or operation of law.

“Permitted Lien” means:

(a)

Liens granted to the Lender after the date of this Note to secure this Note.

(b)

Liens existing on the date of this Note.

(c)

Deposits or pledges to secure payment of workers’ compensation, unemployment insurance, old age pensions or other social security obligations, in the ordinary course of business of the Borrower.

(d)

Liens for taxes, fees, assessments and governmental charges not delinquent at the time of determination.

(e)

Liens of carriers, warehousemen, mechanics and materialmen, and other like Liens arising in the ordinary course of business, for sums not due or to the extent that payment therefor shall not at the time be required to be made at the time of determination.

(f)

Liens incurred or deposits or pledges made or given in connection with, or to secure payment of, indemnity, performance or other similar bonds.

(g)

Liens arising solely by virtue of any statutory or common law provision relating to banker’s liens, rights of set-off or similar rights and remedies as to deposit accounts or other funds maintained with a creditor depository institution; provided that (i) such deposit account is not a dedicated cash collateral account and is not subject to restriction against access by the Borrower in excess of those set forth by regulations promulgated by the Federal Reserve Board, and (ii) such deposit account is not intended by the Borrower to provide collateral to the depository institution.

(h)

Encumbrances in the nature of zoning restrictions, easements and rights or restrictions of record on the use of real property and landlord’s Liens under leases on the premises rented that do not materially detract from the value of such property or impair the use thereof in the business of the Borrower.

(i)

The interest of any lessor under any capitalized lease or purchase money Liens on property; provided, that, such Liens are limited to the property acquired and do not secure indebtedness other than the related capitalized lease obligations or the purchase price of such property.

(j)

Other involuntary Liens imposed upon the Borrower in the ordinary course of business.

If any one or more of the following events (“Events of Default”) shall occur, then, in any such event, the holder hereof may, at its option, declare this Note to be immediately due and payable, together with all unpaid interest accrued hereon, without further notice or demand, but in the case of any of the occurrence of any of events described in paragraphs (c) or (d) below, this Note shall become automatically due and payable, including unpaid interest accrued hereon, without notice or demand:

(a) The Borrower shall default in the due and punctual payment of any installment of either principal of or interest on this Note when the same shall become due and payable and such default shall continue for period of 10 calendar days after written notice from the Lender;

(b) Default in the due observance or performance of any covenant, condition or agreement on the part of the Borrower to be observed or performed pursuant to the terms of this Note, and such default shall continue for period of 10 calendar days after written notice from the Lender;

(c) The Borrower shall (i) apply for or consent to the appointment of a receiver, trustee or liquidator of Borrower or any of Borrower’s properties or assets, (ii) admit in writing Borrower’s inability to pay Borrower’s debts as they mature, (iii) make a general assignment for the benefit of creditors, (iv) be adjudicated a bankrupt or insolvent, or (v) file a voluntary petition in bankruptcy, or a petition or an answer seeking reorganization or an arrangement with creditors to take advantage of any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution or liquidation law or statute, or an answer admitting the material allegations of a petition filed against Borrower in any proceeding under any such law; or

(d) An order, judgment or decree shall be entered, without the application, approval or consent of the Borrower, by any court of competent jurisdiction, approving a petition seeking the reorganization or liquidation of the Borrower or of all or a substantial part of the properties or assets of the Borrower, or appointing a receiver, trustee or liquidator of the Borrower, and such order, judgment or decree shall continue unstayed and in effect for any period of ten days.

If this Note or any payment required to be made thereunder is not paid on the due date (whether at original maturity or following acceleration), the holder hereof shall have, in addition to any other rights it may have under applicable laws, the right to set off the indebtedness evidenced by this Note against any indebtedness of such holder to the Borrower.

No failure or delay on the part of the holder of this Note in exercising any power or right under this Note shall operate as a waiver thereof, nor shall any single or partial exercise of any such power or right preclude any other or further exercise thereof of the exercise of any other power or right. No notice to or demand on the Borrower in any case shall entitle the Borrower to any notice or demand in similar or other circumstances.

The Borrower further agrees to reimburse the holder of this Note upon demand for all reasonable out-of-pocket expenses, including reasonable attorneys’ fees, in connection with such holder’s enforcement of the obligations of the Borrower hereunder.

Presentment and demand for payment, notice of dishonor, protest and notice of protest are hereby waived. In the event of an Event of Default, as set forth above, the Borrower agrees to pay costs of collection and reasonable attorneys’ fees.

Lender agrees, by its acceptance of this Note, to offer, sell or otherwise transfer this Note only in accordance with the provisions of Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”), pursuant to registration under the Securities Act, or pursuant to an available exemption from registration under the Securities Act. In addition, Lender agrees not to engage in hedging transactions with regard to such securities unless in compliance with the Securities Act. Borrower will not register any transfer of this Note unless made in accordance with the foregoing restrictions.

This Note shall be governed by and construed in accordance with the internal laws of the State of Washington (without giving effect to the conflicts of laws principles thereof).

ORAL AGREEMENTS OR ORAL COMMITMENTS TO LOAN MONEY, EXTEND CREDIT OR TO FORBEAR FROM ENFORCING REPAYMENT OF A DEBT ARE NOT ENFORCEABLE UNDER WASHINGTON LAW.

	BIOLIFE SOLUTIONS, INC.

	By:
	Name: Roderick de Greef
	Title: CFO

EXHIBIT B

FORM OF WARRANT

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”). THIS WARRANT MAY NOT BE EXERCISED IN THE UNITED STATES OR BY OR ON BEHALF OF A U.S. PERSON UNLESS REGISTERED UNDER THE U.S. SECURITIES ACT OR AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE. THE TERMS “UNITED STATES” AND “U.S. PERSON” ARE AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT.

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT. SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) IF THE SECURITIES HAVE BEEN REGISTERED, IN COMPLIANCE WITH THE REGISTRATION REQUIREMENTS UNDER THE U.S. SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, (C) IN COMPLIANCE WITH THE EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE U.S. SECURITIES ACT IN ACCORDANCE WITH RULE 144 THEREUNDER, IF APPLICABLE, AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, OR (D) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE STATE LAWS AND REGULATIONS GOVERNING THE OFFER AND SALE OF SECURITIES, AND THE HOLDER HAS, PRIOR TO SUCH SALE, FURNISHED TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING, OR OTHER EVIDENCE OF EXEMPTION, REASONABLY SATISFACTORY TO THE COMPANY. HEDGING TRANSACTIONS INVOLVING SUCH SECURITIES REPRESENTED HEREBY MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE U.S. SECURITIES ACT.

COMMON STOCK PURCHASE WARRANT

biolife solutions, inc.

Warrant Shares: 550,000

Initial Exercise Date: May 12, 2016

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, WAVI Holding AG or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from BioLife Solutions, Inc., a Delaware corporation (the “Company”), up to 550,000 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Section 1. Definitions. In this Warrant, the following terms have the meanings indicated below:

a) “Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close;

b) “Common Stock” means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed;

c) “Common Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock;

d) “Exchange Act” means the United States Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder;

e) “Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

f) “Trading Day” means a day on which the principal Trading Market is open for trading;

g) “Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or the OTC Bulletin Board (or any successors to any of the foregoing); and

h) “VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTC Bulletin Board is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board, (c) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for the Common Stock are then reported in the “Pink Sheets” published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

Section 2. Exercise.

a) Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before 11:59 p.m. (NY Time) on the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly completed and executed (together with, if applicable, a legal opinion of counsel satisfactory to the Company) facsimile copy of the Notice of Exercise in the form annexed hereto and the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

b) Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $1.75, subject to adjustment hereunder (the “Exercise Price”).

c) Cashless Exercise. Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

(A) = the VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless exercise,” as set forth in the applicable Notice of Exercise;

(B) = the Exercise Price of this Warrant, as adjusted hereunder; and

(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

d) Mechanics of Exercise.

i. Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by physical delivery to the address specified by the Holder in the Notice of Exercise by the date that is three (3) Trading Days after the delivery to the Company of the properly completed and executed Notice of Exercise (together with, if applicable, a legal opinion of counsel satisfactory to the Company) (such date, the “Warrant Share Delivery Date”) and the Company’s receipt of payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s check drawn on a United States bank or, if available, pursuant to the cashless exercise procedure specified in Section 2(c) below. The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, having been paid.

ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

iii. [Reserved]

iv. [Reserved]

v. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

vi. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly completed and executed by the Holder and the Company may require, as a condition thereto, evidence satisfactory to the Company that the assignment is in compliance with applicable securities laws and the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.

vii. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

Section 3. Certain Adjustments.

a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

b) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights.

c) Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a "Distribution"), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution.

d) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder, the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.

e) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

f) Notice to Holder.

i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company, the Company shall simultaneously file such notice with the Securities and Exchange Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

Section 4. Transfer of Warrant.

a) Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly completed and executed by the Holder or its agent or attorney (together with evidence satisfactory to the Company that the assignment is registered under the U.S. Securities Act or exempt from such registration requirements) and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued. Notwithstanding the foregoing, the Holder and the Company agree that the Warrant and the securities issuable upon exercise hereof may be transferred only if the Holder has prior thereto provided to the Company written evidence satisfactory to the Company that the transfer is being made in compliance with the provisions of Regulation S under the U.S. Securities Act, pursuant to registration under the U.S. Securities Act or pursuant to an available exemption from registration under the U.S. Securities Act; and the Company shall refuse to register any transfer not made in accordance with the foregoing. The Holder agrees not to engage in hedging transactions with regard to such securities unless in compliance with the U.S. Securities Act.

b) New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

Section 5. Miscellaneous.

a) No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.

b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.

d) Authorized Shares.

The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

e) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of this Warrant), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, then the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant will have restrictions upon resale imposed by state and federal securities laws, including a legend in substantially the following form:

g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

h) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered to the Holder at Paradiesstrasse 25, CH-6845, Jona, Switzerland, or to such other address or addresses as any party may specify in writing to the other party hereto.

i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

l) Amendment. The provisions of this Warrant may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only with the written consent of the Holder and the Company.

m) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

	biolife solutions, inc.

	By:
		Name: Roderick de Greef
		Title: CFO

NOTICE OF EXERCISE

To: biolife solutions, inc.

(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. Payment shall be made in lawful money of the United States.

(2) The undersigned certifies that (check applicable box):

¨ the undersigned is not a U.S. person, is not exercising this Warrant in the United States or for the account or benefit of a U.S. person and has no intention of offering or selling the Warrant Shares in the United States or to, or for the account or benefit of, a U.S. person. The undersigned is acquiring the Warrant Shares solely for its own account, for investment purposes only, and will offer or sell the Warrant Shares only in accordance with the provisions of Regulation S under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), pursuant to registration under the U.S. Securities Act or pursuant to an available exemption from registration under the U.S. Securities Act. The undersigned will not engage in any hedging transactions involving the Warrant Shares unless conducted in compliance with the U.S. Securities Act. The terms “United States” and “U.S. person” are as defined in Regulation S under the U.S. Securities Act; or

¨ the Warrant and the Warrant Shares have been registered under the U.S. Securities Act, or are exempt from registration thereunder, and the undersigned has delivered herewith a written opinion of counsel (which must be satisfactory to the Company) to such effect.

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered to the following address:

If the foregoing address is in the United States, and the undersigned has checked the first box under paragraph 2 above, the Company may require that the undersigned provide additional evidence that the securities are being issued in an “offshore transaction” as defined in Regulation S under the U.S. Securities Act.

[SIGNATURE OF HOLDER]

Name of Investing Entity: _________________________________________________________________________

Signature of Authorized Signatory of Investing Entity: ___________________________________________________

Name of Authorized Signatory: _____________________________________________________________________

Title of Authorized Signatory: ______________________________________________________________________

Date: ________________________________________________________________________________________

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

FOR VALUE RECEIVED, [ ] all of or [ ] the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:
		(Please Print)

Address:
		(Please Print)

Dated: _______________ __, ______

Holder’s Name: ______________________

Holder’s Signature: ___________________

Name and Title of Signatory (if Holder an entity): ______________________________

Holder’s Address: ____________________

NOTE: This Assignment Form must be accompanied by evidence, which must be satisfactory to the Company, that the proposed assignment is being made in compliance with Regulation S under the U.S. Securities Act, pursuant to registration under the U.S. Securities Act, or pursuant to an available exemption under the U.S. Securities Act.

EX-10.7 8 v439570_ex10-7.htm EXHIBIT 10.7

Exhibit 10.7

COMMON STOCK PURCHASE WARRANT

biolife solutions, inc.

Warrant Shares: 550,000

Initial Exercise Date: May 12, 2016

Section 1. Definitions. In this Warrant, the following terms have the meanings indicated below:

b) “Common Stock” means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed;

d) “Exchange Act” means the United States Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder;

f) “Trading Day” means a day on which the principal Trading Market is open for trading;

Section 2. Exercise.

b) Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $1.75, subject to adjustment hereunder (the “Exercise Price”).

(B) = the Exercise Price of this Warrant, as adjusted hereunder; and

d) Mechanics of Exercise.

iii. [Reserved]

iv. [Reserved]

vii. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

Section 3. Certain Adjustments.

f) Notice to Holder.

Section 4. Transfer of Warrant.

Section 5. Miscellaneous.

d) Authorized Shares.

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

	biolife solutions, inc.

	By:	/s/ Roderick de Greef
		Name: Roderick de Greef
		Title: CFO

NOTICE OF EXERCISE

To: biolife solutions, inc.

(2) The undersigned certifies that (check applicable box):

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered to the following address:

[SIGNATURE OF HOLDER]

Name of Investing Entity: _________________________________________________________________________

Signature of Authorized Signatory of Investing Entity: ___________________________________________________

Name of Authorized Signatory: _____________________________________________________________________

Title of Authorized Signatory: ______________________________________________________________________

Date: ________________________________________________________________________________________

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

FOR VALUE RECEIVED, [ ] all of or [ ] the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:
		(Please Print)

Address:
		(Please Print)

Dated: _______________ __, ______

Holder’s Name: ______________________

Holder’s Signature: ___________________

Name and Title of Signatory (if Holder an entity): ______________________________

Holder’s Address: ____________________

EX-10.8 9 v439570_ex10-8.htm EXHIBIT 10.8

Exhibit 10.8

PROMISSORY NOTE

US$4,000,000

May 12, 2016

This Note matures on the Maturity Date, and the outstanding principal amount of this Note shall be repaid in full on the Maturity Date.

This Note is unsecured.

Accrued interest at the rates referred to above shall be payable on the Maturity Date, when all unpaid accrued interest shall be due and payable in full.

Principal, interest and fees owed under this Note are payable in lawful money of the United States of America in immediately available funds.

(2) executed originals of IRS Form W-8ECI;

“Permitted Lien” means:

(a)

Liens granted to the Lender after the date of this Note to secure this Note.

(b)

Liens existing on the date of this Note.

(c)

Deposits or pledges to secure payment of workers’ compensation, unemployment insurance, old age pensions or other social security obligations, in the ordinary course of business of the Borrower.

(d)

Liens for taxes, fees, assessments and governmental charges not delinquent at the time of determination.

(e)

(f)

Liens incurred or deposits or pledges made or given in connection with, or to secure payment of, indemnity, performance or other similar bonds.

(g)

(h)

(i)

(j)

Other involuntary Liens imposed upon the Borrower in the ordinary course of business.

This Note shall be governed by and construed in accordance with the internal laws of the State of Washington (without giving effect to the conflicts of laws principles thereof).

ORAL AGREEMENTS OR ORAL COMMITMENTS TO LOAN MONEY, EXTEND CREDIT OR TO FORBEAR FROM ENFORCING REPAYMENT OF A DEBT ARE NOT ENFORCEABLE UNDER WASHINGTON LAW.

	BIOLIFE SOLUTIONS, INC.

	By:	/s/ Roderick de Greef
	Name: Roderick de Greef
	Title: CFO

EX-31.1 10 v439570_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

RULE 13a-14(a) or RULE 13d-14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934

I, Michael Rice, certify that:

1. I have reviewed this quarterly report on Form 10-Q of BioLife Solutions, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 16, 2016

/s/ Michael Rice
Michael Rice
Chief Executive Officer

EX-31.2 11 v439570_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO

RULE 13a-14(a) or RULE 13d-14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934

I, Roderick de Greef, certify that:

1. I have reviewed this quarterly report on Form 10-Q of BioLife Solutions, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 16, 2016

/s/ Roderick de Greef
Roderick de Greef
Chief Financial Officer

EX-32.1 12 v439570_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioLife Solutions, Inc. (the “Company”) on Form 10-Q for the three month period ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael Rice, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 16, 2016

/s/ Michael Rice
Michael Rice
Chief Executive Officer

EX-32.2 13 v439570_ex32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioLife Solutions, Inc. (the “Company”) on Form 10-Q for the three month period ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Roderick de Greef, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 16, 2016

/s/ Roderick de Greef
Roderick de Greef
Chief Financial Officer

GRAPHIC 14 image_002.jpg GRAPHIC begin 644 image_002.jpg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end EX-101.INS 15 blfs-20160331.xml XBRL INSTANCE DOCUMENT 0000834365 2015-01-01 2015-03-31 0000834365 2016-01-01 2016-03-31 0000834365 2016-03-31 0000834365 2016-05-11 0000834365 2015-12-31 0000834365 2014-12-31 0000834365 2015-03-31 0000834365 us-gaap:FairValueInputsLevel1Member 2016-03-31 0000834365 us-gaap:FairValueInputsLevel2Member 2016-03-31 0000834365 us-gaap:FairValueInputsLevel1Member 2015-12-31 0000834365 us-gaap:FairValueInputsLevel2Member 2015-12-31 0000834365 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2016-01-01 2016-03-31 0000834365 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2015-01-01 2015-03-31 0000834365 blfs:WaviHoldingsAgMember us-gaap:SubsequentEventMember 2016-05-12 0000834365 blfs:WaviHoldingsAgMember us-gaap:SubsequentEventMember 2016-05-01 2016-05-12 0000834365 us-gaap:StockOptionMember 2015-12-31 0000834365 us-gaap:StockOptionMember 2016-01-01 2016-03-31 0000834365 us-gaap:StockOptionMember 2016-03-31 0000834365 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0000834365 us-gaap:WarrantMember 2016-01-01 2016-03-31 0000834365 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0000834365 us-gaap:WarrantMember 2015-01-01 2015-03-31 0000834365 us-gaap:RestrictedStockMember 2016-01-01 2016-03-31 0000834365 us-gaap:RestrictedStockMember 2015-01-01 2015-03-31 0000834365 us-gaap:RestrictedStockMember 2015-12-31 0000834365 us-gaap:RestrictedStockMember 2016-01-01 2016-03-31 0000834365 us-gaap:RestrictedStockMember 2016-03-31 0000834365 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0000834365 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-03-31 0000834365 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-03-31 0000834365 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-03-31 0000834365 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0000834365 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0000834365 us-gaap:CostOfSalesMember 2016-01-01 2016-03-31 0000834365 us-gaap:CostOfSalesMember 2015-01-01 2015-03-31 0000834365 us-gaap:RestrictedStockMember blfs:AmendedRestated2013PerformanceIncentivePlanMember 2016-03-01 2016-03-15 0000834365 us-gaap:RestrictedStockMember blfs:AmendedRestated2013PerformanceIncentivePlanMember 2016-01-01 2016-03-31 0000834365 us-gaap:RestrictedStockMember 2016-03-31 0000834365 us-gaap:SalesRevenueNetMember blfs:CustmerOneMember 2016-01-01 2016-03-31 0000834365 us-gaap:SalesRevenueNetMember blfs:CustmerOneMember 2015-01-01 2015-03-31 0000834365 us-gaap:SalesRevenueNetMember blfs:ZeroCustomerMember 2016-01-01 2016-03-31 0000834365 us-gaap:AccountsReceivableMember blfs:CustmerOneMember 2015-01-01 2015-03-31 0000834365 us-gaap:AccountsReceivableMember blfs:ThreeCustomerMember 2015-01-01 2015-12-31 0000834365 us-gaap:SalesRevenueNetMember 2016-01-01 2016-03-31 0000834365 us-gaap:SalesRevenueNetMember 2015-01-01 2015-03-31 0000834365 blfs:ZeroCustomerMember us-gaap:SalesRevenueNetMember 2015-01-01 2015-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares utr:acre xbrli:pure 10-Q false 2016-03-31 2016 Q1 BIOLIFE SOLUTIONS INC 0000834365 --12-31 Smaller Reporting Company BLFS 12693017

1662431

2173258

1651341

1190260

929289

2018255

1834635

435592

384414

5306538

6972937

1284491

584603

557666

1025521

2894615

2867678

1513071

1421279

1381544

1446399

1836220

1698735

2215385

36166

10775853

12369622

772870

1029373

113340

146438

463558

419766

130216

1479984

1725793

766044 784458

2246028

2510251

12508

12447

72983853

72823398

-451

-65553751

-64326923

1087215

1350900

10775853

12369622

0.001

150000000

12508376

12448391

1852017

1500722

771005

618099

1081012

882623

504239

322165

733913

500255

1335292

1220705

2573444

2043125

-1492432

-1160502

1919

8237

-1490513

-1152265

-263685

-120783

-1226828

-1031482

-0.10

-0.09

12457858

12100588

451

5499

-451

-5499

-263685

-120783

91791

83646

146527

33509

-1792

-40901

260971

-50579

183620

277563

-17324

-72156

91907

221046

10694

-353077

13335 4966

-1593483

-1307852

1650000

2100000

342872

552535

26936

41128

1070529

1716000

32223

24934

12127

24934

-510827

433082

2538758

2971840

-31749

-31750

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <br/> <b>1.</b> <b>Organization and Significant Accounting Policies</b> <b> </b> <b> </b> <b> </b> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Business</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">BioLife Solutions, Inc. (“BioLife,” “us,” “we,” “our,” or the “Company”) is a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers. Our proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. Our biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. Additionally, for our direct, distributor, and contract customers, we perform custom formulation, fill, and finish services.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We have prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full year. These consolidated financial statements and accompanying notes should be read in conjunction with the financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2015 on file with the SEC.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">There have been no material changes to our significant accounting policies as compared to the significant accounting policies described in the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Principles of Consolidation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The consolidated financial statements include the accounts of the Company and its majority-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Concentrations of credit risk and business risk</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In the three months ended March 31, 2016, we derived approximately 12% of our product revenue from one customer. In the three months ended March 31, 2015, we derived approximately 11% of our product revenue from one customer. No other customer accounted for more than 10% of revenue in the three months ended March 31, 2016 or 2015. At March 31, 2016, one customer accounted for approximately 19% of total gross accounts receivable. At December 31, 2015, three customers accounted for approximately 53% of total gross accounts receivable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Revenue from customers located in foreign countries represented 21% of total revenue during the three months ended March 31, 2016 and 2015.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (ASU-2016-09). The updated guidance simplifies and changes how companies account for certain aspects of share-based payment awards to employees, including accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification of certain items in the statement of cash flows. Adoption of ASU 2016-09 is required for fiscal reporting periods beginning after December 15, 2016, including interim reporting periods within those fiscal years with early adoption being permitted. The Company is currently evaluating the potential impact of the pending adoption of ASU 2016-09 on its consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In February 2016, FASB issued Accounting Standards Update No. 2016-02, Leases: Topic 842 (ASU 2016-02) that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. Under the new guidance, leases will continue to be classified as either finance or operating, with classification affecting the pattern of expense recognition in the Consolidated Statements of Operations. Lessor accounting is largely unchanged under ASU 2016-02. Adoption of ASU 2016-02 is required for fiscal reporting periods beginning after December 15, 2018, including interim reporting periods within those fiscal years with early adoption being permitted. The new standard is required to be applied with a modified retrospective approach to each prior reporting period presented with various optional practical expedients. The Company is currently evaluating the potential impact of the pending adoption of ASU 2016-02 on its consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In January 2016, the FASB issued Accounting Standards Update No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities: Topic 825 (ASU 2016-01). The updated guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. Adoption of ASU 2016-01 is required for fiscal reporting periods beginning after December 15, 2017, including interim reporting periods within those fiscal years. The Company is currently evaluating the potential impact of the pending adoption of ASU 2016-01 on its consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In November 2015, FASB issued Accounting Standards Update No. 2015-17, Balance Sheet Classification of Deferred Taxes: Topic 740 (ASU 2015-17). Current GAAP requires the deferred taxes for each jurisdiction to be presented as a net current asset or liability and net noncurrent asset or liability. This requires a jurisdiction-by-jurisdiction analysis based on the classification of the assets and liabilities to which the underlying temporary differences relate, or, in the case of loss or credit carryforwards, based on the period in which the attribute is expected to be realized. Any valuation allowance is then required to be allocated on a pro rata basis, by jurisdiction, between current and noncurrent deferred tax assets. The new guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. As a result, each jurisdiction will now only have one net noncurrent deferred tax asset or liability. The guidance does not change the existing requirement that only permits offsetting within a jurisdiction. Adoption of ASU 2015-17 is required for fiscal reporting periods beginning after December 15, 2016, including interim reporting periods within those fiscal years, and either prospective or retrospective application is permitted. Early adoption of ASU 2015-17 is permitted. At the time of adoption, all of the Company’s deferred tax assets and liabilities, along with any related valuation allowance, will be classified as noncurrent on its Consolidated Balance Sheet. The Company does not plan to early adopt ASU 2015-17.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory: Topic 330 (ASU 2015-11). Topic 330 currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. ASU 2015-11 requires that inventory measured using either the first-in, first-out (FIFO) or average cost method be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Adoption of ASU 2015-11 is required for fiscal reporting periods beginning after December 15, 2016, including interim reporting periods within those fiscal years. The Company does not expect adoption of ASU 2015-11 to have a material impact on its consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On May 28, 2014, FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, Topic 606, requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. Early adoption is not permitted. The updated standard becomes effective for us in the first quarter of fiscal 2018. We have not yet selected a transition method and we are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">With the exception of the new standards discussed above, there have been no new accounting pronouncements not yet effective that have significance, or potential significance, to our Consolidated Financial Statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Principles of Consolidation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The consolidated financial statements include the accounts of the Company and its majority-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Business</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">BioLife Solutions, Inc. (“BioLife,” “us,” “we,” “our,” or the “Company”) is a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers. Our proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. Our biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. Additionally, for our direct, distributor, and contract customers, we perform custom formulation, fill, and finish services.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Concentrations of credit risk and business risk</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In the three months ended March 31, 2016, we derived approximately 12% of our product revenue from one customer. In the three months ended March 31, 2015, we derived approximately 11% of our product revenue from one customer. No other customer accounted for more than 10% of revenue in the three months ended March 31, 2016 or 2015. At March 31, 2016, one customer accounted for approximately 19% of total gross accounts receivable. At December 31, 2015, three customers accounted for approximately 53% of total gross accounts receivable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Revenue from customers located in foreign countries represented 21% of total revenue during the three months ended March 31, 2016 and 2015.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Recent Accounting Pronouncements</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (ASU-2016-09). The updated guidance simplifies and changes how companies account for certain aspects of share-based payment awards to employees, including accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification of certain items in the statement of cash flows. Adoption of ASU 2016-09 is required for fiscal reporting periods beginning after December 15, 2016, including interim reporting periods within those fiscal years with early adoption being permitted. The Company is currently evaluating the potential impact of the pending adoption of ASU 2016-09 on its consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In February 2016, FASB issued Accounting Standards Update No. 2016-02, Leases: Topic 842 (ASU 2016-02) that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. Under the new guidance, leases will continue to be classified as either finance or operating, with classification affecting the pattern of expense recognition in the Consolidated Statements of Operations. Lessor accounting is largely unchanged under ASU 2016-02. Adoption of ASU 2016-02 is required for fiscal reporting periods beginning after December 15, 2018, including interim reporting periods within those fiscal years with early adoption being permitted. The new standard is required to be applied with a modified retrospective approach to each prior reporting period presented with various optional practical expedients. The Company is currently evaluating the potential impact of the pending adoption of ASU 2016-02 on its consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In January 2016, the FASB issued Accounting Standards Update No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities: Topic 825 (ASU 2016-01). The updated guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. Adoption of ASU 2016-01 is required for fiscal reporting periods beginning after December 15, 2017, including interim reporting periods within those fiscal years. The Company is currently evaluating the potential impact of the pending adoption of ASU 2016-01 on its consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In November 2015, FASB issued Accounting Standards Update No. 2015-17, Balance Sheet Classification of Deferred Taxes: Topic 740 (ASU 2015-17). Current GAAP requires the deferred taxes for each jurisdiction to be presented as a net current asset or liability and net noncurrent asset or liability. This requires a jurisdiction-by-jurisdiction analysis based on the classification of the assets and liabilities to which the underlying temporary differences relate, or, in the case of loss or credit carryforwards, based on the period in which the attribute is expected to be realized. Any valuation allowance is then required to be allocated on a pro rata basis, by jurisdiction, between current and noncurrent deferred tax assets. The new guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. As a result, each jurisdiction will now only have one net noncurrent deferred tax asset or liability. The guidance does not change the existing requirement that only permits offsetting within a jurisdiction. Adoption of ASU 2015-17 is required for fiscal reporting periods beginning after December 15, 2016, including interim reporting periods within those fiscal years, and either prospective or retrospective application is permitted. Early adoption of ASU 2015-17 is permitted. At the time of adoption, all of the Company’s deferred tax assets and liabilities, along with any related valuation allowance, will be classified as noncurrent on its Consolidated Balance Sheet. The Company does not plan to early adopt ASU 2015-17.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory: Topic 330 (ASU 2015-11). Topic 330 currently requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. ASU 2015-11 requires that inventory measured using either the first-in, first-out (FIFO) or average cost method be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Adoption of ASU 2015-11 is required for fiscal reporting periods beginning after December 15, 2016, including interim reporting periods within those fiscal years. The Company does not expect adoption of ASU 2015-11 to have a material impact on its consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On May 28, 2014, FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, Topic 606, requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. Early adoption is not permitted. The updated standard becomes effective for us in the first quarter of fiscal 2018. We have not yet selected a transition method and we are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">With the exception of the new standards discussed above, there have been no new accounting pronouncements not yet effective that have significance, or potential significance, to our Consolidated Financial Statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>2. Accumulated Other Comprehensive Loss</strong> <strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following tables show the changes in Accumulated Other Comprehensive Loss by component for the three months ended March 31, 2016:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Three Months Ended<br/> March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Unrealized Loss on Investments, Beginning Balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>(451)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Unrealized Gain on Investments, Current Period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>451</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Unrealized Loss on Investments, Ending Balance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

451

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <strong>3.</strong> <strong>Fair Value Measurement</strong> <strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In accordance with FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” (“ASC Topic 820”), the Company measures its cash and cash equivalents and short term investments at fair value on a recurring basis. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC Topic 820 establishes a three-tier value fair hierarchy, which prioritizes the inputs used in measuring fair value as follows:</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Level 1  Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Level 2  Observable inputs other than quoted prices included in Level 1 for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Level 3  Unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of March 31, 2016 and December 31, 2015, the Company does not have liabilities that are measured at fair value.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following tables set forth the Company’s financial assets measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015, based on the three-tier fair value hierarchy:</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%"> <div style="CLEAR:both;CLEAR: both"> As of March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Bank deposits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">609,247</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">609,247</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Money market funds</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,053,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,053,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,662,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,662,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,662,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,662,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%"> <div style="CLEAR:both;CLEAR: both"> As of December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Bank deposits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">440,809</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">440,809</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Money market funds</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,732,449</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,732,449</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2,173,258</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2,173,258</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Corporate debt securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,401,453</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,401,453</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Commercial paper</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">249,888</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">249,888</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Short term investments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,651,341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,651,341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3,824,599</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3,824,599</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The fair values of bank deposits, money market funds, corporate debt securities and commercial paper classified as Level 1 were derived from quoted market prices as active markets for these instruments exist. The Company has no level 2 or level 3 financial assets. The Company did not have any transfers between Level 1 and Level 2 of the fair value hierarchy during the three months ended March 31, 2016 and the twelve months ended December 31, 2015.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following tables set forth the Company’s financial assets measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015, based on the three-tier fair value hierarchy:</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%"> <div style="CLEAR:both;CLEAR: both"> As of March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Bank deposits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">609,247</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">609,247</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Money market funds</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,053,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,053,184</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,662,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,662,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,662,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,662,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%"> <div style="CLEAR:both;CLEAR: both"> As of December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Bank deposits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">440,809</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">440,809</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Money market funds</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,732,449</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,732,449</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Cash and cash equivalents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2,173,258</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2,173,258</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Corporate debt securities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,401,453</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,401,453</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Commercial paper</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">249,888</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">249,888</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Short term investments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,651,341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,651,341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3,824,599</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3,824,599</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

609247

1053184

1662431

440809

1732449

2173258

1401453

249888

1651341

3824599

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>4. Inventory</strong> <strong>  </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventory consists of the following at March 31, 2016 and December 31, 2015:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="61%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>518,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>299,952</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Work in progress</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>383,297</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>666,124</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,116,489</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>868,559</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,018,255</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,834,635</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

518469

299952

383297

666124

1116489

868559

31749 31750

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>6.</strong> <strong>Share-based Compensation  </strong> <strong> </strong> <strong> </strong> <strong> </strong> <strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Stock Options</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following is a summary of stock option activity for the three month period ended March 31, 2016, and the status of stock options outstanding at March 31, 2016:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> Three Month Period Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="CLEAR:both;CLEAR: both">March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Wtd. Avg.</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Outstanding at beginning of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,555,263</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">265,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.84</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(9,985)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(358,708)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Outstanding at March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,451,570</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Stock options exercisable at March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,185,030</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.43</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of March 31, 2016, there was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">731,042</font> of aggregate intrinsic value of outstanding stock options, including $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">722,956</font> of aggregate intrinsic value of exercisable stock options. Intrinsic value is the total pretax intrinsic value for all “in-the-money” options (i.e., the difference between the Company’s closing stock price on the last trading day of the quarter and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all option holders exercised their options on March 31, 2016. This amount will change based on the fair market value of the Company’s stock. During the quarters ended March 31, 2016 and 2015 intrinsic value of awards exercised was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,253</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,937</font>, respectively.</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The fair value of share-based payments made with stock options to employees and non-employee directors was estimated on the measurement date using the Black-Scholes model using the following weighted average assumptions (N/A for 2015 as no options were granted in that period).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three Month Period Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Expected term (in years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The weighted average grant date fair value of options granted using these assumptions was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.29</font> for the three months ended March 31, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Management applies an estimated forfeiture rate that is derived from historical employee termination data. The estimated forfeiture rate applied for the three month periods ended March 31, 2016 and 2015 was approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8.1</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7.0</font>%, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of March 31, 2016, we had approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,717,280</font> of unrecognized compensation expense related to unvested stock options. We expect to recognize this compensation expense over a weighted average period of approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.05</font> years.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Restricted Stock</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On March 15, 2016 the board granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 200,000</font> restricted stock awards under the Amended & Restated 2013 Performance Incentive Plan. The grants vested <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% immediately with the remainder vesting monthly for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 36</font> months. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following is a summary of restricted stock activity for the three month period ended March 31, 2016, and the status of unvested restricted stock outstanding at March 31, 2016:</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three Month Period Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Number of Restricted Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Grant-Date Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Outstanding at beginning of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">200,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(50,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Outstanding at March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">150,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.90 <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The aggregate fair value of the awards granted during the three months ended March 31, 2016 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">380,000</font> which represents the market value of BioLife common stock on the date that the restricted stock awards were granted. The aggregate fair value of the restricted stock awards that vested for the three months ended March 31, 2016 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">95,000</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We recognized stock compensation expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">98,718</font> for the three months ended March 31, 2016. As of March 31, 2016, there was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">248,399</font> in unrecognized compensation costs related to restricted stock awards. We expect to recognize those costs over <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.96</font> years.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>We recorded stock compensation expense for the three month periods ended March 31, 2016 and 2015, as follows:</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three Month Period Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Research and development costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">37,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6,944</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Sales and marketing costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">63,499</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,755</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">General and administrative costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">77,510</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,773</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Cost of product sales</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(31,951)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">13,037</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">146,527</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">33,509</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the three month period ended March 31, 2016, we recorded forfeited unvested stock compensation expense in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,317</font> to cost of product sales and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">51,817</font> to general and administrative costs related to unvested stock options forfeited upon termination of certain employees.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following is a summary of stock option activity for the three month period ended March 31, 2016, and the status of stock options outstanding at March 31, 2016:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> Three Month Period Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="CLEAR:both;CLEAR: both">March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Wtd. Avg.</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Outstanding at beginning of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,555,263</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">265,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.84</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(9,985)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(358,708)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Outstanding at March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,451,570</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Stock options exercisable at March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,185,030</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.43</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The fair value of share-based payments made with stock options to employees and non-employee directors was estimated on the measurement date using the Black-Scholes model using the following weighted average assumptions (N/A for 2015 as no options were granted in that period).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three Month Period Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Expected term (in years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>7. Warrants</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">At March 31, 2016 and December 31, 2015, we had <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,195,997</font></font> warrants outstanding and exercisable with a weighted average exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.60</font></font>. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The outstanding warrants have expiration dates between August 2016 and March 2021.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

20096

13989 0 66640 0

4000000

2017-06-01

0.1

550000

1.75

P5Y

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <b>9. Commitments & Contingencies</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Leases</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We lease approximately 30,000 square feet in our Bothell, Washington headquarters. The term of our lease continues until July 31, 2021 with two options to extend the term of the lease, each of which is for an additional period of five years, with the first extension term commencing, if at all, on August 1, 2021, and the second extension term commencing, if at all, immediately following the expiration of the first extension term. In accordance with the amended lease agreement, our monthly base rent is approximately $59,700, with scheduled annual increases each August and again in October for the most recent amendment. We are also required to pay an amount equal to the Company’s proportionate share of certain taxes and operating expenses.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Employment agreements</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We have employment agreements with the Chief Executive Officer, Chief Financial Officer, Chief Technology Officer, Vice President of Operations, Vice President, Marketing and Vice President, Global Sales. None of these employment agreements is for a definitive period, but rather each will continue indefinitely until terminated in accordance with its terms. The agreements provide for a base annual salary, payable in monthly (or shorter) installments. In addition, the agreement with the Chief Executive Officer provides for incentive bonuses at the discretion of the Board of Directors. Under certain conditions and for certain of these officers, we may be required to pay additional amounts upon terminating the officer or upon the officer resigning for good reason.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>biologistex</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Our biologistex joint venture committed to purchase approximately $2.4 million in Smart Containers from SAVSU. As of March 31, 2016, the purchase commitment is $2.1 million.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Litigation</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none of which are currently material to the Company’s business.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

2555263

265000

9985

358708

59700

2400000

2100000

30000

2021-07-31

P5Y

2451570

1185030

2451570

7195997

1368528

7428141

1.80

150000

1.84

1.40

2.15

1.43

1.75

7195997

4.60

7195997

4.60

The outstanding warrants have expiration dates between August 2016 and March 2021.

0.0165

0.0

P7Y

0.75

200000

150000

50000

1.90

37469

6944

63499

5755

77510

7773

-31951

13037

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following is a summary of restricted stock activity for the three month period ended March 31, 2016, and the status of unvested restricted stock outstanding at March 31, 2016:</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three Month Period Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Number of Restricted Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Grant-Date Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Outstanding at beginning of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">N/A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">200,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(50,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Outstanding at March 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">150,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.90 <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

200000

0.25

P36M

380000

95000

248399

P2Y11M16D

40317

51817

0.081 0.070

1717280

P3Y18D

731042

722956

4253

20937

1.29

98718

The agreement calls for WAVI to provide four $1 million tranches at specified times throughout the next 12 months.

1124790 1124790 407279 375530 717511 749260 178749 165414

896260

914674

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Basic weighted average common shares outstanding, and the potentially dilutive securities excluded from loss per share computations because they are anti-dilutive, are as follows as of March 31, 2016 and 2015, respectively:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three Month Period Ended<br/> March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Basic and diluted weighted average common stock shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">12,457,858</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">12,100,588</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Potentially dilutive securities excluded from loss per share computations:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Common stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,451,570</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,368,528</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Common stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,195,997</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,428,141</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div style="CLEAR:both;CLEAR: both">Restricted stock unvested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">150,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.12

0.11

0.1

0.19

0.53

0.21 0.21

0.1

7442610

8508471

8529825

9859371

-1490062

-1146766

-1226377

-1025983

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> 5. <strong>Deferred Rent  </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Deferred rent consists of the following at March 31, 2016 and December 31, 2015:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="61%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Landlord-funded leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,124,790</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,124,790</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Less accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(407,279)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(375,530)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>717,511</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>749,260</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Straight line rent adjustment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>178,749</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>165,414</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Total deferred rent</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>896,260</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>914,674</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the three month periods ended March 31, 2016 and 2015, the Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">31,749</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">31,750</font>, respectively, in deferred rent amortization of these landlord funded leasehold improvements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Straight line rent adjustment represents the difference between cash rent payments and the recognition of rent expense on a straight-line basis over the terms of the lease.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Deferred rent consists of the following at March 31, 2016 and December 31, 2015:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 1.8pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="61%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Landlord-funded leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,124,790</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,124,790</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Less accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(407,279)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(375,530)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>717,511</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>749,260</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Straight line rent adjustment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>178,749</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>165,414</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Total deferred rent</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>896,260</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>914,674</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We have prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In management’s opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full year. These consolidated financial statements and accompanying notes should be read in conjunction with the financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2015 on file with the SEC.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">There have been no material changes to our significant accounting policies as compared to the significant accounting policies described in the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2015.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0 334640

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <b>10. Subsequent Events</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Credit Facility</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On May 12, 2016 we entered into a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4</font> million credit facility agreement with our largest shareholder WAVI Holding AG (“WAVI”). The agreement calls for WAVI to provide four $1 million tranches at specified times throughout the next 12 months. The related promissory note matures on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">June 1, 2017</font>, and is unsecured, but senior to any existing debt. In addition, we have agreed not to pledge or secure our assets for any other obligations outside the normal course of our business. The promissory note carries an annual interest rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% and WAVI was issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> year warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 550,000</font> shares of common stock at a fixed exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.75</font> per share.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>MNX Relationship</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">I<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">n April, we f</font>ormed a relationship with MNX Global Logistics, a specialty courier offering door to door, same day and next flight out managed logistics in order to increase the attractiveness of our product offering by offering value-added ancillary logistics services for time and temperature sensitive biologic materials.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

EX-101.SCH 16 blfs-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Organization and Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Fair Value Measurement link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Inventory link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Deferred Rent link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Share-based Compensation link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Warrants link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Net Loss per Common Share link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Commitments And Contingencies link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Organization and Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Inventory (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Deferred Rent (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Share-based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Net Loss per Common Share (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Organization and Significant Accounting Policies (Details Narrative) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Accumulated Other Comprehensive Loss (Details) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Fair Value Measurement (Details) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Inventory (Details) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Deferred Rent (Details) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Deferred Rent (Details Narrative) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Share-based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Share-based Compensation (Details 1) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Share-based Compensation (Details 2) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Share-based Compensation (Details 3) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Share-based Compensation (Details Narrative) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Warrants (Details Narrative) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Net Loss per Common Share (Details) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Commitments And Contingencies (Details Narrative) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 17 blfs-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 18 blfs-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 19 blfs-20160331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Statement of Financial Position [Abstract] Assets [Abstract] Assets Current assets Current assets Cash and cash equivalents Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Short term investments Short term investments Accounts receivable, trade, net of allowance for doubtful accounts of $0 at December 31, 2015 and 2014 Accounts receivable, trade, net of allowance for doubtful accounts of $0 at March 31, 2016 and December 31, 2015 Inventories Inventories Total Prepaid expenses and other current assets Prepaid expenses and other current assets Assets, Current, Total Total current assets Property and equipment Property and equipment Leasehold Improvements, Gross Leasehold improvements Furniture and computer equipment Furniture and computer equipment Manufacturing and other equipment Manufacturing and other equipment Property, Plant and Equipment, Gross, Ending Balance Subtotal Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Less: Accumulated depreciation Property, Plant and Equipment, Net Net property and equipment Internal use software Internal use software Intangible asset Intangible asset Long term deposits Long term deposits Assets Total assets Liabilities and Shareholders' Equity Liabilities and Shareholders’ Equity Current liabilities Current liabilities Accounts payable Accounts payable Accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued compensation Accrued compensation Deferred rent, current portion Deferred rent Liabilities, Current, Total Total current liabilities Long term liabilities Long term liabilities Deferred rent, long term Deferred rent, long term Deferred rent, long term as on the reporting period. Liabilities, Total Total liabilities Commitments and Contingencies (Note 10) Commitments and contingencies (Note 9) Shareholders' equity Shareholders’ equity Common stock, $0.001 par value; 150,000,000 shares authorized, 12,448,391 and 12,084,859 shares issued and outstanding at December 31, 2015 and 2014 Common stock, $0.001 par value; 150,000,000 shares authorized, 12,508,376 and 12,448,391 shares issued and outstanding at March 31, 2016 and December 31, 2015 Additional paid-in capital Additional paid-in capital Accumulated other comprehensive loss Accumulated other comprehensive loss Unrealized Loss on Investments, Beginning Balance Unrealized Loss on Investments, Ending Balance Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Total BioLife Solutions, Inc. shareholders' equity StockholdersEquity StockholdersEquity Total non-controlling interest equity Total non-controlling interest equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance Total shareholders' equity Liabilities and Equity, Total Total liabilities and shareholders’ equity Accounts receivable allowances Common stock, par value Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] Sales Revenue, Goods, Net, Total Product revenue Product sales Cost of product sales Cost of product sales Gross Profit Gross profit Research and development Research and development Sales and marketing Sales and marketing General and administrative General and administrative Operating Expenses Total operating expenses Operating loss Operating loss Operating Expenses [Abstract] Operating expenses Interest income Interest income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Loss Net loss Net Income (Loss) Attributable to Noncontrolling Interest Net loss attributable to non-controlling interest Net Income (Loss) Attributable to Parent Net Loss attributable to BioLife Solutions, Inc. Basic and diluted net loss per common share Basic and diluted net loss per common share attributable to BioLife Solutions, Inc. (in dollars per share) Basic and diluted weighted average common shares used to calculate net loss per common share Basic and diluted weighted average common shares used to calculate net loss per common share (in dollars per share) Basic and diluted weighted average common shares used to calculate net loss per common share Basic and diluted weighted average common stock shares outstanding Statement of Comprehensive Income [Abstract] Other comprehensive income (loss) Other comprehensive income Unrealized gain (loss) on available-for-sale investments Unrealized gain on available-for-sale investments Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent, Total Total other comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total Comprehensive loss attributable to non-controlling interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total Comprehensive loss attributable to BioLife Solutions, Inc. Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities Adjustments to reconcile net loss to net cash provided by operating activities Adjustments to reconcile net loss to net cash used in operating activities Depreciation Depreciation Stock-based compensation Stock-based compensation expense Total Share Based Compensation Amortization of Lease Incentives Amortization of deferred rent related to lease incentives Change in operating assets and liabilities Change in operating assets and liabilities Increase (Decrease) in Accounts Receivable (Increase) Decrease in Accounts receivable, trade Increase (Decrease) in Inventories Inventories Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expenses and other current assets Increase (Decrease) in Increase (Decrease) in Accounts Payable, Total Accounts payable Accrued compensation and other current liabilities Accrued compensation and other current liabilities Deferred rent Deferred rent Deferred rent. Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities Sales/maturities of available-for-sale investments Sales of available-for-sale investments Payments to Acquire Investments, Total Purchases of available-for-sale investments Payments to Develop Software Costs associated with internal use software development Payments to Acquire Property, Plant, and Equipment, Total Purchase of property and equipment Net Cash Provided by (Used in) Investing Activities, Continuing Operations, Total Net cash provided by investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities Proceeds from exercise of common stock options and warrants Proceeds from exercise of common stock options Payments of Stock Issuance Costs Deferred costs related to security issuance Net Cash Provided by (Used in) Financing Activities, Continuing Operations, Total Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease), Total Net increase (decrease) in cash and cash equivalents Conversion of notes payable Costs incurred for capitalized internal use software not paid as of quarter end (amounts are included in liabilities) Conversion of notes payable Accounting Policies [Abstract] Organization and Significant Accounting Policies Organization and Significant Accounting Policies Equity [Abstract] Comprehensive Income (Loss) Note [Text Block] Accumulated Other Comprehensive Loss Fair Value Disclosures [Abstract] Fair Value Measurement Fair Value Measurement Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Inventory Deferred Rent Disclosure [Abstract] Stockholders' Equity Note [Abstract] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Warrants Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Share-based Compensation Commitments and Contingencies Disclosure [Abstract] Commitments & Contingencies Business Description and Accounting Policies [Text Block] Business Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Principles of Consolidation Principles of Consolidation Concentrations of credit risk and business risk Concentrations of credit risk and business risk Recent accounting pronouncements Changes in Accumulated Other Comprehensive Loss Changes in Accumulated Other Comprehensive Loss Fair Value Assets Measured on Recurring Basis Fair Value Assets Measured on Recurring Basis Schedule of Inventory, Current [Table Text Block] Inventories Summary of stock option activity Summary of stock option activity Weighted average assumptions of share based payment Weighted average assumptions of share based payment Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Share-based Compensation, Restricted Stock and Restricted Stock Units Activity Stock compensation expense Stock compensation expense Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, before Tax Unrealized Loss on Investments, Current Period Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Bank deposits Bank deposits Money market funds Money market funds Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Financial Instruments, Owned, Corporate Debt, at Fair Value Corporate debt securities Commercial Paper, at Carrying Value Commercial paper Available-for-sale Securities Short term investments AvailableForSaleSecurities Total Total Raw materials Raw materials Work in progress Work in progress Finished goods Finished goods Leasehold Improvements Gross1 Landlord-funded leasehold improvements Leasehold improvements gross1. Less accumulated amortization Less accumulated amortization Less accumulated amortization. Leasehold Improvements Total Leasehold improvements. Straight line rent adjustment Straight line rent adjustment Straight line rent adjustment. Total deferred rent Total deferred rent Deferred Rent [Table] PropertyPlantAndEquipmentByType [Axis] Property, Plant and Equipment, Type [Domain] Landlord Funded Leasehold Improvements [Member] Deferred Rent [Line Items] Deferred Rent Amortization Deferred Rent Amortization Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Type of Deferred Compensation [Axis] Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain] Equity Option [Member] Common stock options Statement [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Shares Number of Shares Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options, Ending Balance Outstanding at beginning of year, Shares Outstanding at March 31, 2016 ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions Granted Granted, Shares Stock option/warrant exercises - Shares Stock option/warrant exercises - Shares Exercised, Shares Forfeited, Shares Forfeited, Shares Wtd. Avg. Exercise Price Wtd. Avg. Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance Outstanding at beginning of year Outstanding at March 31, 2016 Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted Granted, Wtd. Avg. Shares Exercise Price Exercised Exercised, Wtd. Avg. Shares Exercise Price Forfeited Forfeited, Wtd. Avg. Shares Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable at year end Stock options exercisable at March 31, 2016 Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Trading Symbol Entity Filer Category Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Class of Stock [Domain] Other income (expenses) Other income Accretion (Amortization) of Discounts and Premiums, Investments Accretion and amortization on available for sale investments Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Accumulated Other Comprehensive Income (Loss) [Line Items] Equity Component [Domain] Inventory, Current [Table] Inventory [Axis] Inventory [Domain] EX-101.PRE 20 blfs-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 21 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2016	May. 11, 2016
Document Information [Line Items]
Entity Registrant Name	BIOLIFE SOLUTIONS INC
Entity Central Index Key	0000834365
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		12,693,017
Trading Symbol	BLFS
Entity Filer Category	Smaller Reporting Company
Document Period End Date	Mar. 31, 2016
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2016

XML 22 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 1,662,431	$ 2,173,258
Short term investments	0	1,651,341
Accounts receivable, trade, net of allowance for doubtful accounts of $0 at March 31, 2016 and December 31, 2015	1,190,260	929,289
Inventories	2,018,255	1,834,635
Prepaid expenses and other current assets	435,592	384,414
Total current assets	5,306,538	6,972,937
Property and equipment
Leasehold improvements	1,284,491	1,284,491
Furniture and computer equipment	584,603	557,666
Manufacturing and other equipment	1,025,521	1,025,521
Subtotal	2,894,615	2,867,678
Less: Accumulated depreciation	(1,513,071)	(1,421,279)
Net property and equipment	1,381,544	1,446,399
Internal use software	1,836,220	1,698,735
Intangible asset	2,215,385	2,215,385
Long term deposits	36,166	36,166
Total assets	10,775,853	12,369,622
Current liabilities
Accounts payable	772,870	1,029,373
Accrued expenses and other current liabilities	113,340	146,438
Accrued compensation	463,558	419,766
Deferred rent	130,216	130,216
Total current liabilities	1,479,984	1,725,793
Long term liabilities
Deferred rent, long term	766,044	784,458
Total liabilities	$ 2,246,028	$ 2,510,251
Commitments and contingencies (Note 9)
Shareholders’ equity
Common stock, $0.001 par value; 150,000,000 shares authorized, 12,508,376 and 12,448,391 shares issued and outstanding at March 31, 2016 and December 31, 2015	$ 12,508	$ 12,447
Additional paid-in capital	72,983,853	72,823,398
Accumulated other comprehensive loss	0	(451)
Accumulated deficit	(65,553,751)	(64,326,923)
Total BioLife Solutions, Inc. shareholders' equity	7,442,610	8,508,471
Total non-controlling interest equity	1,087,215	1,350,900
Total shareholders' equity	8,529,825	9,859,371
Total liabilities and shareholders’ equity	$ 10,775,853	$ 12,369,622

XML 23 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Accounts receivable allowances	$ 0	$ 0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	12,508,376	12,448,391
Common stock, outstanding	12,508,376	12,448,391

XML 24 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($)	3 Months Ended
Consolidated Statements of Operations - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Product revenue	$ 1,852,017	$ 1,500,722
Cost of product sales	771,005	618,099
Gross profit	1,081,012	882,623
Operating expenses
Research and development	504,239	322,165
Sales and marketing	733,913	500,255
General and administrative	1,335,292	1,220,705
Total operating expenses	2,573,444	2,043,125
Operating loss	(1,492,432)	(1,160,502)
Other income
Interest income	1,919	8,237
Net Loss	(1,490,513)	(1,152,265)
Net loss attributable to non-controlling interest	263,685	120,783
Net Loss attributable to BioLife Solutions, Inc.	$ (1,226,828)	$ (1,031,482)
Basic and diluted net loss per common share attributable to BioLife Solutions, Inc. (in dollars per share)	$ (0.10)	$ (0.09)
Basic and diluted weighted average common shares used to calculate net loss per common share (in dollars per share)	12,457,858	12,100,588

XML 25 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended
Consolidated Statements of Comprehensive Loss - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Net loss	$ (1,490,513)	$ (1,152,265)
Other comprehensive income
Unrealized gain on available-for-sale investments	451	5,499
Total other comprehensive income	451	5,499
Comprehensive loss	(1,490,062)	(1,146,766)
Comprehensive loss attributable to non-controlling interest	263,685	120,783
Comprehensive loss attributable to BioLife Solutions, Inc.	$ (1,226,377)	$ (1,025,983)

XML 26 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities
Net loss	$ (1,490,513)	$ (1,152,265)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	91,791	83,646
Stock-based compensation expense	146,527	33,509
Amortization of deferred rent related to lease incentives	(31,749)	(31,750)
Accretion and amortization on available for sale investments	1,792	40,901
Change in operating assets and liabilities
(Increase) Decrease in Accounts receivable, trade	(260,971)	50,579
Inventories	(183,620)	(277,563)
Prepaid expenses and other current assets	17,324	72,156
Increase (Decrease) in
Accounts payable	91,907	221,046
Accrued compensation and other current liabilities	10,694	(353,077)
Deferred rent	13,335	4,966
Net cash used in operating activities	(1,593,483)	(1,307,852)
Cash flows from investing activities
Sales of available-for-sale investments	1,650,000	2,100,000
Purchases of available-for-sale investments	0	(342,872)
Costs associated with internal use software development	(552,535)	0
Purchase of property and equipment	(26,936)	(41,128)
Net cash provided by investing activities	1,070,529	1,716,000
Cash flows from financing activities
Proceeds from exercise of common stock options	32,223	24,934
Deferred costs related to security issuance	(20,096)	0
Net cash provided by financing activities	12,127	24,934
Net increase (decrease) in cash and cash equivalents	(510,827)	433,082
Cash and cash equivalents - beginning of period	2,173,258	2,538,758
Cash and cash equivalents - end of period	1,662,431	2,971,840
Non-cash investing activity
Costs incurred for capitalized internal use software not paid as of quarter end (amounts are included in liabilities)	0	334,640
Option exercises for which cash not yet received as of quarter end	13,989	0
Deferred costs related to security issuance not yet paid as of quarter end	$ 66,640	$ 0

XML 27 R7.htm IDEA: XBRL DOCUMENT

Organization and Significant Accounting Policies

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Organization and Significant Accounting Policies

1. Organization and Significant Accounting Policies

Business

Basis of Presentation

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its majority-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

Concentrations of credit risk and business risk

Revenue from customers located in foreign countries represented 21% of total revenue during the three months ended March 31, 2016 and 2015.

Recent Accounting Pronouncements

XML 28 R8.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Loss

3 Months Ended

Mar. 31, 2016

Equity [Abstract]

Accumulated Other Comprehensive Loss

2. Accumulated Other Comprehensive Loss

The following tables show the changes in Accumulated Other Comprehensive Loss by component for the three months ended March 31, 2016:

	Three Months Ended March 31, 2016
Unrealized Loss on Investments, Beginning Balance	$	(451)
Unrealized Gain on Investments, Current Period		451
Unrealized Loss on Investments, Ending Balance	$	––

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

XML 29 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurement

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurement

3. Fair Value Measurement

Level 1 – Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 3 – Unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

As of March 31, 2016 and December 31, 2015, the Company does not have liabilities that are measured at fair value.

The following tables set forth the Company’s financial assets measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015, based on the three-tier fair value hierarchy:

As of March 31, 2016	Level 1		Level 2		Total
Bank deposits	$	609,247	$	—	$	609,247
Money market funds		1,053,184		—		1,053,184
Cash and cash equivalents		1,662,431		—		1,662,431
Total	$	1,662,431	$	—	$	1,662,431

As of December 31, 2015	Level 1		Level 2		Total
Bank deposits	$	440,809	$	—	$	440,809
Money market funds		1,732,449		—		1,732,449
Cash and cash equivalents		2,173,258		—		2,173,258
Corporate debt securities		1,401,453		—		1,401,453
Commercial paper		249,888		—		249,888
Short term investments		1,651,341		—		1,651,341
Total	$	3,824,599	$	—	$	3,824,599

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 30 R10.htm IDEA: XBRL DOCUMENT

Inventory

3 Months Ended

Mar. 31, 2016

Inventory Disclosure [Abstract]

Inventory

4. Inventory

Inventory consists of the following at March 31, 2016 and December 31, 2015:

	March 31, 2016		December 31, 2015
Raw materials	$	518,469	$	299,952
Work in progress		383,297		666,124
Finished goods		1,116,489		868,559
Total	$	2,018,255	$	1,834,635

XML 31 R11.htm IDEA: XBRL DOCUMENT

Deferred Rent

3 Months Ended

Mar. 31, 2016

Deferred Rent Disclosure [Abstract]

Deferred Rent

5. Deferred Rent

Deferred rent consists of the following at March 31, 2016 and December 31, 2015:

	March 31, 2016		December 31, 2015
Landlord-funded leasehold improvements	$	1,124,790	$	1,124,790
Less accumulated amortization		(407,279)		(375,530)
Total		717,511		749,260
Straight line rent adjustment		178,749		165,414
Total deferred rent	$	896,260	$	914,674

During the three month periods ended March 31, 2016 and 2015, the Company recorded $31,749 and $31,750, respectively, in deferred rent amortization of these landlord funded leasehold improvements.

Straight line rent adjustment represents the difference between cash rent payments and the recognition of rent expense on a straight-line basis over the terms of the lease.

XML 32 R12.htm IDEA: XBRL DOCUMENT

Share-based Compensation

3 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-based Compensation

6. Share-based Compensation

Stock Options

The following is a summary of stock option activity for the three month period ended March 31, 2016, and the status of stock options outstanding at March 31, 2016:

	Three Month Period Ended
	March 31, 2016
				Wtd. Avg.
				Exercise
		Options		Price
Outstanding at beginning of year			2,555,263	$	1.80
Granted			265,000	$	1.84
Exercised			(9,985)	$	1.40
Forfeited			(358,708)	$	2.15
Outstanding at March 31, 2016			2,451,570	$	1.75

Stock options exercisable at March 31, 2016			1,185,030	$	1.43

	Three Month Period Ended
	March 31,
	2016			2015
Risk free interest rate		1.65	%		N/A
Dividend yield		0.0	%		N/A
Expected term (in years)		7			N/A
Volatility		75	%		N/A

The weighted average grant date fair value of options granted using these assumptions was $1.29 for the three months ended March 31, 2016.

Restricted Stock

	Three Month Period Ended
	March 31, 2016
	Number of Restricted Shares		Grant-Date Fair Value
Outstanding at beginning of year		—	$	N/A
Granted		200,000	$	1.90
Vested		(50,000)	$	1.90
Outstanding at March 31, 2016		150,000	$	1.90

We recorded stock compensation expense for the three month periods ended March 31, 2016 and 2015, as follows:

	Three Month Period Ended
	March 31,
	2016		2015
Research and development costs	$	37,469	$	6,944
Sales and marketing costs		63,499		5,755
General and administrative costs		77,510		7,773
Cost of product sales		(31,951)		13,037
Total	$	146,527	$	33,509

XML 33 R13.htm IDEA: XBRL DOCUMENT

Warrants

3 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

Warrants

7. Warrants

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 34 R14.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Net Loss per Common Share

8. Net Loss per Common Share

	Three Month Period Ended March 31,
	2016		2015
Basic and diluted weighted average common stock shares outstanding		12,457,858		12,100,588
Potentially dilutive securities excluded from loss per share computations:
Common stock options		2,451,570		1,368,528
Common stock purchase warrants		7,195,997		7,428,141
Restricted stock unvested		150,000		—

XML 35 R15.htm IDEA: XBRL DOCUMENT

Commitments And Contingencies

3 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments & Contingencies

9. Commitments & Contingencies

Leases

Employment agreements

biologistex

Our biologistex joint venture committed to purchase approximately $2.4 million in Smart Containers from SAVSU. As of March 31, 2016, the purchase commitment is $2.1 million.

Litigation

From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none of which are currently material to the Company’s business.

XML 36 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

Subsequent Events

10. Subsequent Events

Credit Facility

MNX Relationship

XML 37 R17.htm IDEA: XBRL DOCUMENT

Organization and Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Business

Business

Basis of Presentation

Basis of Presentation

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its majority-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

Concentrations of credit risk and business risk

Concentrations of credit risk and business risk

Revenue from customers located in foreign countries represented 21% of total revenue during the three months ended March 31, 2016 and 2015.

Recent accounting pronouncements

Recent Accounting Pronouncements

XML 38 R18.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Loss (Tables)

3 Months Ended

Mar. 31, 2016

Equity [Abstract]

Changes in Accumulated Other Comprehensive Loss

The following tables show the changes in Accumulated Other Comprehensive Loss by component for the three months ended March 31, 2016:

	Three Months Ended March 31, 2016
Unrealized Loss on Investments, Beginning Balance	$	(451)
Unrealized Gain on Investments, Current Period		451
Unrealized Loss on Investments, Ending Balance	$	––

XML 39 R19.htm IDEA: XBRL DOCUMENT

Fair Value Measurement (Tables)

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Assets Measured on Recurring Basis

The following tables set forth the Company’s financial assets measured at fair value on a recurring basis as of March 31, 2016 and December 31, 2015, based on the three-tier fair value hierarchy:

As of March 31, 2016	Level 1		Level 2		Total
Bank deposits	$	609,247	$	—	$	609,247
Money market funds		1,053,184		—		1,053,184
Cash and cash equivalents		1,662,431		—		1,662,431
Total	$	1,662,431	$	—	$	1,662,431

As of December 31, 2015	Level 1		Level 2		Total
Bank deposits	$	440,809	$	—	$	440,809
Money market funds		1,732,449		—		1,732,449
Cash and cash equivalents		2,173,258		—		2,173,258
Corporate debt securities		1,401,453		—		1,401,453
Commercial paper		249,888		—		249,888
Short term investments		1,651,341		—		1,651,341
Total	$	3,824,599	$	—	$	3,824,599

XML 40 R20.htm IDEA: XBRL DOCUMENT

Inventory (Tables)

3 Months Ended

Mar. 31, 2016

Inventory Disclosure [Abstract]

Inventories

Inventory consists of the following at March 31, 2016 and December 31, 2015:

	March 31, 2016		December 31, 2015
Raw materials	$	518,469	$	299,952
Work in progress		383,297		666,124
Finished goods		1,116,489		868,559
Total	$	2,018,255	$	1,834,635

XML 41 R21.htm IDEA: XBRL DOCUMENT

Deferred Rent (Tables)

3 Months Ended

Mar. 31, 2016

Deferred Rent Disclosure [Abstract]

Deferred rent

Deferred rent consists of the following at March 31, 2016 and December 31, 2015:

	March 31, 2016		December 31, 2015
Landlord-funded leasehold improvements	$	1,124,790	$	1,124,790
Less accumulated amortization		(407,279)		(375,530)
Total		717,511		749,260
Straight line rent adjustment		178,749		165,414
Total deferred rent	$	896,260	$	914,674

XML 42 R22.htm IDEA: XBRL DOCUMENT

Share-based Compensation (Tables)

3 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of stock option activity

The following is a summary of stock option activity for the three month period ended March 31, 2016, and the status of stock options outstanding at March 31, 2016:

	Three Month Period Ended
	March 31, 2016
				Wtd. Avg.
				Exercise
		Options		Price
Outstanding at beginning of year			2,555,263	$	1.80
Granted			265,000	$	1.84
Exercised			(9,985)	$	1.40
Forfeited			(358,708)	$	2.15
Outstanding at March 31, 2016			2,451,570	$	1.75

Stock options exercisable at March 31, 2016			1,185,030	$	1.43

Weighted average assumptions of share based payment

	Three Month Period Ended
	March 31,
	2016			2015
Risk free interest rate		1.65	%		N/A
Dividend yield		0.0	%		N/A
Expected term (in years)		7			N/A
Volatility		75	%		N/A

Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

The following is a summary of restricted stock activity for the three month period ended March 31, 2016, and the status of unvested restricted stock outstanding at March 31, 2016:

	Three Month Period Ended
	March 31, 2016
	Number of Restricted Shares		Grant-Date Fair Value
Outstanding at beginning of year		—	$	N/A
Granted		200,000	$	1.90
Vested		(50,000)	$	1.90
Outstanding at March 31, 2016		150,000	$	1.90

Stock compensation expense

We recorded stock compensation expense for the three month periods ended March 31, 2016 and 2015, as follows:

	Three Month Period Ended
	March 31,
	2016		2015
Research and development costs	$	37,469	$	6,944
Sales and marketing costs		63,499		5,755
General and administrative costs		77,510		7,773
Cost of product sales		(31,951)		13,037
Total	$	146,527	$	33,509

XML 43 R23.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share (Tables)

3 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Loss Per share computation

	Three Month Period Ended March 31,
	2016		2015
Basic and diluted weighted average common stock shares outstanding		12,457,858		12,100,588
Potentially dilutive securities excluded from loss per share computations:
Common stock options		2,451,570		1,368,528
Common stock purchase warrants		7,195,997		7,428,141
Restricted stock unvested		150,000		—

XML 44 R24.htm IDEA: XBRL DOCUMENT

Organization and Significant Accounting Policies (Details Narrative)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Sales Revenue, Net [Member]
Revenue from customers located in foreign countries	21.00%	21.00%
Sales Revenue, Net [Member] \| One Customer [Member]
Concentration Risk, Percentage	12.00%	11.00%
Sales Revenue, Net [Member] \| Zero Customer [Member]
Concentration Risk, Percentage	10.00%	10.00%
Accounts Receivable [Member] \| One Customer [Member]
Concentration Risk, Percentage		19.00%
Accounts Receivable [Member] \| Three Customer [Member]
Concentration Risk, Percentage			53.00%

XML 45 R25.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Loss (Details)	3 Months Ended
Accumulated Other Comprehensive Loss (Details)	Mar. 31, 2016 USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Unrealized Loss on Investments, Beginning Balance	$ (451)
Unrealized Loss on Investments, Current Period	451
Unrealized Loss on Investments, Ending Balance	$ 0

XML 46 R26.htm IDEA: XBRL DOCUMENT

Fair Value Measurement (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Bank deposits	$ 609,247	$ 440,809
Money market funds	1,053,184	1,732,449
Cash and cash equivalents	1,662,431	2,173,258
Corporate debt securities		1,401,453
Commercial paper		249,888
Short term investments		1,651,341
Total	1,662,431	3,824,599
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Bank deposits	609,247	440,809
Money market funds	1,053,184	1,732,449
Cash and cash equivalents	1,662,431	2,173,258
Corporate debt securities		1,401,453
Commercial paper		249,888
Short term investments		1,651,341
Total	1,662,431	3,824,599
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Bank deposits	0	0
Money market funds	0	0
Cash and cash equivalents	0	0
Corporate debt securities		0
Commercial paper		0
Short term investments		0
Total	$ 0	$ 0

XML 47 R27.htm IDEA: XBRL DOCUMENT

Inventory (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Inventory [Line Items]
Raw materials	$ 518,469	$ 299,952
Work in progress	383,297	666,124
Finished goods	1,116,489	868,559
Total	$ 2,018,255	$ 1,834,635

XML 48 R28.htm IDEA: XBRL DOCUMENT

Deferred Rent (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Deferred Rent [Line Items]
Landlord-funded leasehold improvements	$ 1,124,790	$ 1,124,790
Less accumulated amortization	(407,279)	(375,530)
Total	717,511	749,260
Straight line rent adjustment	178,749	165,414
Total deferred rent	$ 896,260	$ 914,674

XML 49 R29.htm IDEA: XBRL DOCUMENT

Deferred Rent (Details Narrative) - USD ($)	3 Months Ended
Deferred Rent (Details Narrative) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Landlord Funded Leasehold Improvements [Member]
Deferred Rent [Line Items]
Deferred Rent Amortization	$ 31,749	$ 31,750

XML 50 R30.htm IDEA: XBRL DOCUMENT

Share-based Compensation (Details) - Common stock options	3 Months Ended
	Mar. 31, 2016 $ / shares shares
Number of Shares
Outstanding at beginning of year, Shares \| shares	2,555,263
Granted, Shares \| shares	265,000
Exercised, Shares \| shares	(9,985)
Forfeited, Shares \| shares	(358,708)
Outstanding at March 31, 2016 \| shares	2,451,570
Stock options exercisable at March 31, 2016 \| shares	1,185,030
Wtd. Avg. Exercise Price
Outstanding at beginning of year \| $ / shares	$ 1.80
Granted, Wtd. Avg. Shares Exercise Price \| $ / shares	1.84
Exercised, Wtd. Avg. Shares Exercise Price \| $ / shares	1.40
Forfeited, Wtd. Avg. Shares Exercise Price \| $ / shares	2.15
Outstanding at March 31, 2016 \| $ / shares	1.75
Stock options exercisable at March 31, 2016 \| $ / shares	$ 1.43

XML 51 R31.htm IDEA: XBRL DOCUMENT

Share-based Compensation (Details 1)	3 Months Ended
Share-based Compensation (Details 1)	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.65%
Dividend yield	0.00%
Expected term (in years)	7 years
Volatility	75.00%

XML 52 R32.htm IDEA: XBRL DOCUMENT

Share-based Compensation (Details 2) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of year \| shares	0
Number of Restricted Shares,Granted \| shares	200,000
Number of Restricted Shares,Vested \| shares	(50,000)
Outstanding at March 31, 2016 \| shares	150,000
Outstanding at beginning of year \| $ / shares
Grant-Date Fair Value,Granted \| $ / shares	$ 1.90
Grant-Date Fair Value,Vested \| $ / shares	1.90
Outstanding at March 31, 2016 \| $ / shares	$ 1.90

XML 53 R33.htm IDEA: XBRL DOCUMENT

Share-based Compensation (Details 3) - USD ($)	3 Months Ended
Share-based Compensation (Details 3) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total Share Based Compensation	$ 146,527	$ 33,509
Research and development costs
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total Share Based Compensation	37,469	6,944
Sales and marketing costs
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total Share Based Compensation	63,499	5,755
General and administrative costs
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total Share Based Compensation	77,510	7,773
Cost of product sales
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total Share Based Compensation	$ (31,951)	$ 13,037

XML 54 R34.htm IDEA: XBRL DOCUMENT

Share-based Compensation (Details Narrative) - USD ($)		3 Months Ended
Share-based Compensation (Details Narrative) - USD ($)	Mar. 15, 2016	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 1,717,280
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		3 years 18 days
Estimated Forfeiture Rate		8.10%	7.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		$ 731,042
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		722,956
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 4,253	$ 20,937
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 1.29
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense		$ 98,718
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Restricted Stock Award, Forfeitures, Total		40,317
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Restricted Stock Award, Forfeitures, Total		51,817
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 248,399
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 11 months 16 days
Amended Restated 2013 Performance Incentive Plan [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	200,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		36 months
Stock Issued During Period, Value, Restricted Stock Award, Gross		$ 380,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 95,000

XML 55 R35.htm IDEA: XBRL DOCUMENT

Warrants (Details Narrative) - USD ($)	3 Months Ended
Warrants (Details Narrative) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding	$ 7,195,997	$ 7,195,997
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.60	$ 4.60
Outstanding Warrants Expiration Dates	The outstanding warrants have expiration dates between August 2016 and March 2021.

XML 56 R36.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share (Details) - shares	3 Months Ended
Net Loss per Common Share (Details) - shares	Mar. 31, 2016	Mar. 31, 2015
Net Loss per Common Share [Line Items]
Basic and diluted weighted average common stock shares outstanding	12,457,858	12,100,588
Common stock options
Net Loss per Common Share [Line Items]
Potentially dilutive securities excluded from loss per share computations	2,451,570	1,368,528
Common stock purchase warrants
Net Loss per Common Share [Line Items]
Potentially dilutive securities excluded from loss per share computations	7,195,997	7,428,141
Restricted stock unvested
Net Loss per Common Share [Line Items]
Potentially dilutive securities excluded from loss per share computations	150,000	0

XML 57 R37.htm IDEA: XBRL DOCUMENT

Commitments And Contingencies (Details Narrative)	3 Months Ended
Commitments And Contingencies (Details Narrative)	Mar. 31, 2016 USD ($) a
Loss Contingencies [Line Items]
Operating Leases, Rent Expense, Minimum Rentals	$ 59,700
Long-term Purchase Commitment, Amount	2,400,000
Purchase Commitment, Remaining Minimum Amount Committed	$ 2,100,000
Area of Land \| a	30,000
Lease Expiration Date	Jul. 31, 2021
Lessee Leasing Arrangements, Operating Leases, Renewal Term	5 years

XML 58 R38.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	May. 12, 2016	Mar. 31, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.60	$ 4.60
Wavi Holdings AG [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 4
Line of Credit Facility, Expiration Date	Jun. 01, 2017
Line of Credit Facility, Interest Rate During Period	10.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	550,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.75
Warrants Expiration term	5 years
Line of Credit Facility, Description	The agreement calls for WAVI to provide four $1 million tranches at specified times throughout the next 12 months.

EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 46 182 1 false 20 0 false 5 false false R1.htm 101 - Document - Document And Entity Information Sheet http://biolifesolutions.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Consolidated Balance Sheets Sheet http://biolifesolutions.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 103 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://biolifesolutions.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 104 - Statement - Consolidated Statements of Operations Sheet http://biolifesolutions.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 105 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://biolifesolutions.com/role/ConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 106 - Statement - Consolidated Statements of Cash Flows Sheet http://biolifesolutions.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 107 - Disclosure - Organization and Significant Accounting Policies Sheet http://biolifesolutions.com/role/OrganizationAndSignificantAccountingPolicies Organization and Significant Accounting Policies Notes 7 false false R8.htm 108 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://biolifesolutions.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 8 false false R9.htm 109 - Disclosure - Fair Value Measurement Sheet http://biolifesolutions.com/role/FairValueMeasurement Fair Value Measurement Notes 9 false false R10.htm 110 - Disclosure - Inventory Sheet http://biolifesolutions.com/role/Inventory Inventory Notes 10 false false R11.htm 111 - Disclosure - Deferred Rent Sheet http://biolifesolutions.com/role/DeferredRent Deferred Rent Notes 11 false false R12.htm 112 - Disclosure - Share-based Compensation Sheet http://biolifesolutions.com/role/SharebasedCompensation Share-based Compensation Notes 12 false false R13.htm 113 - Disclosure - Warrants Sheet http://biolifesolutions.com/role/Warrants Warrants Notes 13 false false R14.htm 114 - Disclosure - Net Loss per Common Share Sheet http://biolifesolutions.com/role/NetLossPerCommonShare Net Loss per Common Share Notes 14 false false R15.htm 115 - Disclosure - Commitments And Contingencies Sheet http://biolifesolutions.com/role/CommitmentsAndContingencies Commitments And Contingencies Notes 15 false false R16.htm 116 - Disclosure - Subsequent Events Sheet http://biolifesolutions.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 117 - Disclosure - Organization and Significant Accounting Policies (Policies) Sheet http://biolifesolutions.com/role/OrganizationAndSignificantAccountingPoliciesPolicies Organization and Significant Accounting Policies (Policies) Policies http://biolifesolutions.com/role/OrganizationAndSignificantAccountingPolicies 17 false false R18.htm 118 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://biolifesolutions.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://biolifesolutions.com/role/AccumulatedOtherComprehensiveLoss 18 false false R19.htm 119 - Disclosure - Fair Value Measurement (Tables) Sheet http://biolifesolutions.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://biolifesolutions.com/role/FairValueMeasurement 19 false false R20.htm 120 - Disclosure - Inventory (Tables) Sheet http://biolifesolutions.com/role/InventoryTables Inventory (Tables) Tables http://biolifesolutions.com/role/Inventory 20 false false R21.htm 121 - Disclosure - Deferred Rent (Tables) Sheet http://biolifesolutions.com/role/DeferredRentTables Deferred Rent (Tables) Tables http://biolifesolutions.com/role/DeferredRent 21 false false R22.htm 122 - Disclosure - Share-based Compensation (Tables) Sheet http://biolifesolutions.com/role/SharebasedCompensationTables Share-based Compensation (Tables) Tables http://biolifesolutions.com/role/SharebasedCompensation 22 false false R23.htm 123 - Disclosure - Net Loss per Common Share (Tables) Sheet http://biolifesolutions.com/role/NetLossPerCommonShareTables Net Loss per Common Share (Tables) Tables http://biolifesolutions.com/role/NetLossPerCommonShare 23 false false R24.htm 124 - Disclosure - Organization and Significant Accounting Policies (Details Narrative) Sheet http://biolifesolutions.com/role/OrganizationAndSignificantAccountingPoliciesDetailsNarrative Organization and Significant Accounting Policies (Details Narrative) Details http://biolifesolutions.com/role/OrganizationAndSignificantAccountingPoliciesPolicies 24 false false R25.htm 125 - Disclosure - Accumulated Other Comprehensive Loss (Details) Sheet http://biolifesolutions.com/role/AccumulatedOtherComprehensiveLossDetails Accumulated Other Comprehensive Loss (Details) Details http://biolifesolutions.com/role/AccumulatedOtherComprehensiveLossTables 25 false false R26.htm 126 - Disclosure - Fair Value Measurement (Details) Sheet http://biolifesolutions.com/role/FairValueMeasurementDetails Fair Value Measurement (Details) Details http://biolifesolutions.com/role/FairValueMeasurementTables 26 false false R27.htm 127 - Disclosure - Inventory (Details) Sheet http://biolifesolutions.com/role/InventoryDetails Inventory (Details) Details http://biolifesolutions.com/role/InventoryTables 27 false false R28.htm 128 - Disclosure - Deferred Rent (Details) Sheet http://biolifesolutions.com/role/DeferredRentDetails Deferred Rent (Details) Details http://biolifesolutions.com/role/DeferredRentTables 28 false false R29.htm 129 - Disclosure - Deferred Rent (Details Narrative) Sheet http://biolifesolutions.com/role/DeferredRentDetailsNarrative Deferred Rent (Details Narrative) Details http://biolifesolutions.com/role/DeferredRentTables 29 false false R30.htm 130 - Disclosure - Share-based Compensation (Details) Sheet http://biolifesolutions.com/role/SharebasedCompensationDetails Share-based Compensation (Details) Details http://biolifesolutions.com/role/SharebasedCompensationTables 30 false false R31.htm 131 - Disclosure - Share-based Compensation (Details 1) Sheet http://biolifesolutions.com/role/SharebasedCompensationDetails1 Share-based Compensation (Details 1) Details http://biolifesolutions.com/role/SharebasedCompensationTables 31 false false R32.htm 132 - Disclosure - Share-based Compensation (Details 2) Sheet http://biolifesolutions.com/role/SharebasedCompensationDetails2 Share-based Compensation (Details 2) Details http://biolifesolutions.com/role/SharebasedCompensationTables 32 false false R33.htm 133 - Disclosure - Share-based Compensation (Details 3) Sheet http://biolifesolutions.com/role/SharebasedCompensationDetails3 Share-based Compensation (Details 3) Details http://biolifesolutions.com/role/SharebasedCompensationTables 33 false false R34.htm 134 - Disclosure - Share-based Compensation (Details Narrative) Sheet http://biolifesolutions.com/role/SharebasedCompensationDetailsNarrative Share-based Compensation (Details Narrative) Details http://biolifesolutions.com/role/SharebasedCompensationTables 34 false false R35.htm 135 - Disclosure - Warrants (Details Narrative) Sheet http://biolifesolutions.com/role/WarrantsDetailsNarrative Warrants (Details Narrative) Details http://biolifesolutions.com/role/Warrants 35 false false R36.htm 136 - Disclosure - Net Loss per Common Share (Details) Sheet http://biolifesolutions.com/role/NetLossPerCommonShareDetails Net Loss per Common Share (Details) Details http://biolifesolutions.com/role/NetLossPerCommonShareTables 36 false false R37.htm 137 - Disclosure - Commitments And Contingencies (Details Narrative) Sheet http://biolifesolutions.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments And Contingencies (Details Narrative) Details http://biolifesolutions.com/role/CommitmentsAndContingencies 37 false false R38.htm 138 - Disclosure - Subsequent Events (Details Narrative) Sheet http://biolifesolutions.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://biolifesolutions.com/role/SubsequentEvents 38 false false All Reports Book All Reports blfs-20160331.xml blfs-20160331.xsd blfs-20160331_cal.xml blfs-20160331_def.xml blfs-20160331_lab.xml blfs-20160331_pre.xml true true ZIP 65 0001144204-16-102533-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-16-102533-xbrl.zip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